Prediction of outcome in breast cancer patients using gene expression profiling by Oh, Daniel S.
  
 
 
Prediction of Outcome in Breast Cancer Patients Using Gene 
Expression Profiling 
 
 
 
Daniel S. Oh 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Curriculum in Genetics and Molecular Biology.  
 
 
 
 
Chapel Hill 
2006 
 
 
 
 
 
                               Approved by 
 
             
                                 Advisor: Dr. Charles Perou 
 
 
                            Dr. Albert Baldwin 
 
        
                               Dr. Channing Der 
 
        
                            Dr. Mayetri Gupta 
 
 
                            Dr. Beverly Mitchell 
 ii
 
 
 
ABSTRACT 
Daniel S. Oh 
Prediction of Outcome in Breast Cancer Patients Using Gene Expression Profiling 
(Under the Direction of Charles M. Perou) 
 
Breast cancer, the most common cancer diagnosed in women, is a complex and 
heterogeneous disease. In order to make the best treatment decision for a breast cancer 
patient, it is important to accurately determine that patient’s risk of recurrence and the 
therapy to which that patient’s tumor is most likely to respond. The prognostic and/or 
predictive factors currently accepted for use in primary breast cancer decision making 
(i.e. lymph node status, tumor size, nuclear grade, etc.) are not enough to accurately 
identify those patients who may require therapy and gives little information about what 
therapy they might best benefit from. Recent discoveries using gene expression profiling 
have greatly improved our understanding of the molecular pathogenesis of breast cancer. 
We believe that gene expression profiling may also improve the prognostication and/or 
prediction of breast cancer outcomes, and thus, the main objective of this work has been 
to develop and test gene expression-based predictors of outcome in breast cancer patients. 
First, we developed an expression-based predictor of outcome for Estrogen Receptor 
(ER) and/or Progesterone Receptor (PR)-positive breast cancer patients using biological 
differences among these tumors. Second, we developed a predictor for objectively 
classifying tumors into one of five intrinsic subtypes and validated this using multiple test 
 iii
sets. Next, using a single patient dataset, we determined the concordance in outcome 
predictions made by several different gene expression profiles (developed on different 
platforms by different laboratories). Lastly, we developed gene expression-based 
predictors for response to neoadjuvant chemotherapy. In summary, this work shows that 
gene expression profiling holds great promise in being clinically useful in the treatment 
decision-making process for breast cancer patients.  
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CHAPTER 1:  INTRODUCTION 
Breast cancer, the most common cancer diagnosed and the second leading cause 
of cancer death among women in the US, is a complex and heterogeneous disease. It is 
critically important for clinicians to accurately determine which breast cancer patients are 
likely to show recurrence and what treatments they will best benefit from. Currently, the 
factors widely accepted for use in prognostication and/or prediction for breast cancer 
patients include axillary lymph node status, age, tumor size, estrogen and progesterone 
receptor status, and histologic grade1,2. Researchers have attempted to find other factors 
useful for predicting outcomes, but many of these have failed to become clinically useful. 
There is a need to improve on this set of factors currently used in breast cancer prognosis 
and prediction, as many patients are either being unnecessarily overtreated or being 
treated with toxic and expensive chemotherapeutics to which they will not show a 
response. For example, current guidelines recommend that most lymph node metastasis-
negative patients should undergo systemic adjuvant chemotherapy; however, a majority 
of these node-negative patients are being unnecessarily overtreated because if left 
systemically untreated, approximately only 20% would develop recurrence3.  
  Gene expression profiling using DNA microarrays has recently begun to be used 
to investigate the heterogeneous nature of breast cancer. It has allowed for a better 
understanding of the biological differences within breast cancer beyond the traditional 
methods of patient stratification (i.e. stratification by ER status)4. We believe it may also 
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provide a way to improve the outcome prediction and treatment decision-making for 
breast cancer patients. Gene expression profiling was used by Perou and colleagues to 
classify breast cancer into a luminal epithelial, basal-like, normal breast-like, and 
HER2+/ER- subtypes4, which were shown to have significant differences in patient 
outcome5,6 (Figure 1). This classification was done by hierarchical cluster analysis7 of 
tumors using an ‘intrinsic’ gene set, which consisted of genes with significantly greater 
variation in expression between tumors than between paired samples from the same 
tumor. The subtypes identified by Perou et al.4 were distinguished by extensive 
differences in expression of genes from the ‘intrinsic’ gene list (Figure 2). The luminal 
epithelial subtype of breast cancer was found to be mainly composed of ER+ and/or PR+ 
tumors and correlated with the high expression of a cluster of genes (luminal 
epithelial/ER+ gene cluster), which included ER and GATA3. In contrast, the basal-like 
subtype was found to have low expression of the ER+ gene cluster, but high expression 
of a cluster of genes that included cytokeratins 5, 6, and 17. The HER2+/ER- subtype 
also showed low expression of the ER+ gene cluster, but had high expression of HER2 
and other genes in the ERBB2 (HER2) amplicon such as GRB74. Thus, these analyses 
rediscovered important breast cancer biomarkers (i.e. ER and HER2) but also identified 
new “subtypes” of breast cancer. 
  
Estrogen Receptor Biology and Tamoxifen Resistance. The estrogen receptor 
(ER) belongs to the superfamily of nuclear hormone receptors that includes the 
progesterone receptor (PR) and thyroid hormone receptor. ER is essential for mammary 
gland differentiation and morphogenesis as evidenced by the dramatic phenotypes seen in 
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ER-knock-out mice8. Upon binding to estrogen, ER undergoes a conformational change 
that results in dissociation from an inhibitory heat shock protein complex, followed by 
receptor dimerization and phosphorylation9. The activated ER then binds to target gene 
promoters at specific palindromic sequence motifs called estrogen response elements 
(EREs)10, which leads to alterations in the transcription of these estrogen-regulated genes. 
Genes regulated by estrogen have diverse functions, including promotion of the cell cycle 
and proliferation, cell-cell interactions, angiogenesis, and inhibition of apoptosis11-14. In 
addition, it is postulated that estrogen-regulated genes include those involved in 
inhibition of tumor cell invasion and metastasis8.  
Positive regulation of estrogen-regulated genes is mediated by two different 
domains in ER, AF-1 and AF-2. AF-1 is located at the N-terminal of ER and is hormone-
independent, while AF-2 is located in the ligand-binding domain of ER and is hormone-
dependent10. Co-activator proteins such as SRC1, TIF2, and AIB1 form a complex with 
ER on the promoter to positively regulate transcription, partly through recruitment of 
histone-acetyltransferases to the promoter, which results in chromatin decondensation9. 
Negative regulation of transcription by ER is controversial and less well understood, and 
is thought to involve recruitment of corepressor proteins such as NCoR1 and NCoR2 
which in turn recruit histone-deacetylase complexes, which results in chromatin 
condensation15,16.  
Modulation of gene expression by ER has also been shown to occur at non-ERE 
sites such as AP-1 and SP-1 regulatory sequences9. At these regulatory sequences, ER 
does not directly bind to DNA, but rather is attached to the promoter complex by 
interaction with other DNA-bound transcription factors (TFs) such as c-jun and c-fos. ER 
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modulates the activity of these TFs by stabilizing their DNA binding and/or recruiting 
additional coactivators to the complex17. In addition, it is believed that ER may also have 
non-genomic activity, in which ligand binding to membrane-bound or cytoplasmic ER 
causes it to interact with a variety of membrane-signaling molecules including key 
growth-factor receptors and/or growth-factor dependent kinases (i.e. IGF-1R, PI3K, 
MAPK, EGFR, and HER2)18,19. These kinases can then activate signaling cascades that 
may enhance the activity of nuclear ER and its coregulators via phosphorylation20. 
It is widely believed that estrogen, via the estrogen receptor, is involved in the 
pathogenesis of and sustains the growth of ER+ breast cancers. Thus, patients with ER+ 
breast cancer are given estrogen antagonists that block ER activity. The most widely used 
hormone antagonist is tamoxifen, a selective ER modulator (SERM) that binds ER and 
blocks its activity in the breast. Tamoxifen is the gold standard of treatment for ER+ 
breast cancer patients; however, up to 40% of these patients experience relapse despite 
receiving therapy21-23.  
Postulated tamoxifen resistance mechanisms include loss of ER 
expression/function and altered expression of a second ER (referred to as ERß) whose 
function in normal and malignant breast cells is poorly understood20. However, other 
postulated resistance mechanisms have received more attention and are believed to be 
more important: (1) alterations in co-regulatory proteins such as overexpression of the ER 
co-activator AIB1 and (2) the upregulation of growth factor signaling pathways such as 
those mediated by EGFR and HER2 that are believed to engage in cross-talk with ER 
signaling pathways as described earlier19,24. Clinical and laboratory studies suggest that 
high levels of AIB1 may enhance the partial agonistic effect of tamoxifen and therefore 
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contribute to tamoxifen resistance25,26. Clinical and experimental evidence indicate that 
overexpression of HER2 and/or EGFR is associated with and contributes to tamoxifen 
resistance27,28. It is hypothesized that one reason HER2 and/or EGFR overexpression 
contributes to tamoxifen resistance is that the subsequent increased activation of 
downstream kinases can activate and enhance ER activity by phosphorylating ER and its 
coregulators24. 
 
Outcome prediction in hormone-receptor positive breast cancer. Currently, 
the prognosis of a patient with ER+ and/or PR+ breast cancer can be highly variable. A 
subgroup of patients with this type of breast cancer (i.e. luminal) experiences disease 
relapse regardless of receiving therapy while other subsets do extremely well21-23. The 
“intrinsic” classification of Luminal A vs. Luminal B is predictive of outcomes in ER+ 
and/or PR+ patients; however, this distinction is correlated with grade and we believed it 
possible to develop a more biologically relevant predictor of outcomes for this patient 
subset. Not enough progress has been made in developing methods to predict which ER+ 
and/or PR+ patients are at risk or not at risk for experiencing relapse. Such a method of 
defining the prognosis of ER+ and/or PR+ breast cancer patients would be of significant 
value.  
Pathways under the control of estrogen signaling (mediated by the estrogen 
receptor) are involved in the growth and differentiation of the mammary gland and are 
widely believed to be important in ER+ and/or PR+ breast cancer biology8,9. Thus, we 
speculated that gene expression profiling of the ER pathway using cell line models might 
be useful in developing a clinically robust outcome predictor for ER+ and/or PR+ breast 
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cancer and lead to a better understanding of the biological differences within this breast 
cancer tumor type. Because of the widely believed importance of estrogen responsiveness 
and signaling in ER+ and/or PR+ breast cancer biology, we hypothesized that estrogen-
regulated genes might be useful in predicting outcome in this type of breast cancer, and 
therefore, we developed an ER-pathway based predictor for breast cancer patients that is 
described in Chapter 2. 
 
Microarray platform-independent validation of the “intrinsic” breast tumor 
subtypes. A major challenge for microarray studies, especially those with clinical 
implications, is validation29,30. Due to the practical barriers of cost and access to large 
numbers of fresh frozen tumor samples with associated clinical information, very few 
microarray studies have analyzed enough samples to allow promising initial findings to 
be sufficiently validated to justify the major investment required for clinical testing. An 
efficient approach would be to use public gene expression data repositories as test sets; 
however, it has been difficult to compare and/or combine data sets from independent 
laboratories due to differences in sample preparation, experimental design, and 
microarray platforms. Fortunately, the multivariate analysis tool Distance Weighted 
Discrimination (DWD) has recently been shown to successfully overcome this difficulty 
in comparing and/or combining datasets from independent laboratories31. DWD identifies 
systemic biases present in separate microarray datasets and makes a global adjustment to 
these datasets to compensate for these biases. If one considers each separate dataset as a 
multi-dimensional cloud of data points, DWD works by taking two such clouds and 
shifting one such that it more optimally overlaps the other. 
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The “intrinsic” subtypes identified by Perou and colleagues (described above) has 
not yet been validated as a predictor/prognosticator of breast cancer patient outcomes to 
the extent that other gene expression-based predictive/prognostic profiles have32,33. Thus, 
in Chapter 3 we used DWD to (1) validate the intrinsic subtypes on independent test 
datasets generated on differing microarray platforms and (2) constructed a method to 
objectively assign any given tumor to an intrinsic tumor subtype. 
 
Concordance of several different gene expression-based predictors. Many 
different laboratories have examined the prognostic and/or predictive utility of gene 
expression profiling for breast cancer. These predictors include the discovery of the 
“intrinsic” subtypes using supervised hierarchical clustering analysis as done by Perou 
and colleagues as described above. Independently, van’t Veer and colleagues identified a 
70-gene prognostic signature that classifies tumors into either a good or poor prognosis 
group34. This signature was obtained through a supervised analysis in which genes were 
selected according to correlation with patient outcome for a set of 78 node-negative 
breast cancer patients all less than 55 years of age at time of diagnosis. Genes involved in 
cell cycle, invasion and metastasis, angiogenesis, and signal transduction were found to 
be significantly upregulated in the poor prognosis signature34.  
Chang and colleagues35,36 characterized the transcriptional response of normal 
fibroblasts to serum and showed that this “wound-response signature” can predict 
outcomes in breast cancer patients. Patients whose tumors expressed the wound-response 
signature (“activated” tumors) had markedly poor overall survival and distant metastasis-
free survival compared to patients with tumors that did not express this signature 
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(“quiescent” tumors). The wound-response signature included induction of genes 
involved in the cell cycle, cell motility, extracellular matrix remodeling, and cell-cell 
signaling35. Lastly, two laboratories independently derived expression-based predictors of 
outcome in ER+ tamoxifen-treated patients. First, Paik and colleagues developed a qRT-
PCR-based 21-gene prognostic score (referred to as the “Recurrence score”) for node-
negative tamoxifen-treated breast cancers, and used it to successfully categorize patients 
as having a low, intermediate, or high risk of recurrence37. Second, Ma and colleagues 
determined that a 2-gene ratio (HOXB13:IL17BR) could predict disease-free survival in 
tamoxifen-treated patients: a high ratio indicated a poor clinical outcome compared to a 
low ratio38.  
These different gene expression-based predictors were developed by different 
laboratories, and a comparison of the gene lists from some of these predictors showed 
that they overlapped each other by only a modest amount, if at all. This lower than 
expected gene similarity between lists might be explained by differences in microarray 
platforms, cohort biases due to different patient selection criteria and sample size, and 
differences in statistical methods used to develop the predictors. An important and 
unanswered question is whether the lack in gene overlap between these predictors reflects 
an actual discordance in outcome predictions for the individual patient (i.e. do these 
different predictors actually disagree or agree concerning outcome predictions for the 
individual patient). To answer this question, in Chapter 4 we describe our studies where 
we performed an analysis of a single patient dataset on which the five 
prognostic/predictive gene expression-based predictors described above (intrinsic 
subtypes4, van’t Veer et al’s 70-gene predictor34, Chang et al’s Wound-Response 
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predictor35, the Recurrence score predictor37, and Ma et al’s 2-gene ratio predictor38) were 
simultaneously compared. 
 
Prediction of neoadjuvant chemotherapy response. The identification of 
biomarkers that predict chemotherapy response in breast cancer is an area of intense 
research, in large part because no such predictor currently exists. In some cases, cell 
proliferation index or TP53 somatic mutation status has been correlated with response, 
but these markers are not in standard use for patient stratification39-42. Recently, response 
studies have focused on using DNA microarrays to identify gene expression patterns 
predictive of chemotherapy response. Neoadjuvant chemotherapy (treatment before 
primary surgery) facilitates these response studies because it allows for the direct and 
timely observation of tumor response to treatment and allows access to primary tumor 
samples before and during treatment to develop and assess markers that might be 
predictive of response3.  
An additional reason why we may want to study neoadjuvant chemotherapy 
response is that it has been shown to be correlated with, and can be used as a surrogate 
marker, for improved long-term disease-free and overall survival43-49. For example, in a 
study of 372 patients given neoadjuvant chemotherapy, Kuerer et al.44 reported that the 5-
year overall and disease-free survival rates were significantly higher in those achieving 
Pathological Complete Response (pCR) compared to those who did not. Likewise, in a 
study of 158 patients, Chang et al.47 reported that good clinical response (defined by 
Chang et al. as clinical complete response or minimal residual disease) to neoadjuvant 
chemotherapy was significantly associated with decreased risk of relapse and death. 
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Thus, encouraged by these neoadjuvant studies, in Chapter 5 we determined whether 
gene expression patterns from pre-treatment tumor samples could predict response to 
neoadjuvant chemotherapy.  
In summary, this work builds on that of Perou and others regarding the 
heterogeneity of breast cancer. The overall aim of this work has been to use this 
knowledge about the heterogeneity of breast cancer to develop/analyze gene expression-
based predictors of outcome in breast cancer patients. In all of our aims, we were 
successful in developing expression-based predictors that provided added value, and thus, 
we believe that the results of our analyses will improve the outcomes of future breast 
cancer patients. 
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FIGURES 
 
 
Figure 1.1. Kaplan-Meier analysis of disease outcome in two patient cohorts stratified by 
intrinsic subtype. A. Time to development of distant metastasis in the 97 sporadic cases 
from van’t Veer et al. B. Overall survival for 72 patients with locally advanced breast 
cancer in the Norway cohort. Figure adapted from Sorlie et al.6 
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Figure 1.2. Hierarchical cluster analysis using the “intrinsic” gene set. Gene expression 
patterns of 85 experimental samples (78 carcinomas, 3 benign tumors, and four normal 
tissues) were analyzed by hierarchical clustering using the 476 cDNA intrinsic clone set. 
A. The tumor specimens were divided into subtypes based on differences in gene 
expression. The cluster dendrogram showing the subtypes of tumors are colored as: 
luminal subtype A, dark blue; luminal subtype B, yellow; luminal subtype C, light blue; 
normal breast-like, green; basal-like, red; and ERBB2+, pink. B. Scaled-down 
representation of the complete cluster diagram. C. ERBB2 amplicon cluster. D. Novel 
unknown cluster. E. Basal epithelial cell-enriched cluster. F. Normal breast-like cluster. 
G. Luminal epithelial gene cluster containing ER. Figure adapted from Sorlie et al.5 
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ABSTRACT 
Purpose 
The prognosis of a patient with Estrogen Receptor (ER) and/or Progesterone Receptor 
(PR)-positive breast cancer can be highly variable. Therefore, we developed a gene 
expression-based outcome predictor for ER+ and/or PR+ (i.e. Luminal) breast cancer 
patients using biological differences among these tumors.  
 
Materials and Methods 
The ER+ MCF-7 breast cancer cell line was treated with 17β-estradiol to identify 
estrogen-regulated genes. These genes were used to develop an outcome predictor on a 
training set of 65 luminal epithelial primary breast carcinomas. The outcome predictor 
was then validated on three independent published datasets.  
 
Results 
The estrogen-induced gene set identified in MCF-7 cells was used to hierarchically 
cluster a 65 tumor training set into 2 groups, which showed significant differences in 
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survival (p=0.0004). Supervised analyses identified 822 genes that optimally defined 
these two groups, with the poor prognosis Group IIE showing high expression of cell 
proliferation and anti-apoptosis genes. The good prognosis Group IE showed high 
expression of estrogen and GATA3-regulated genes. Mean expression profiles (i.e. 
centroids) created for each group were applied to ER+ and/or PR+ tumors from three 
published datasets. For all datasets, Kaplan-Meier survival analyses showed significant 
differences in Relapse-Free and Overall Survival between Group IE and IIE tumors. 
Multivariate Cox analysis of the largest test dataset showed that this predictor added 
significant prognostic information independent of standard clinical predictors and other 
gene expression-based predictors. 
 
Conclusion 
This study provides new biological information concerning differences within hormone 
receptor-positive breast cancers and a means of predicting long-term outcomes in 
tamoxifen-treated patients. 
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INTRODUCTION 
Breast cancers are traditionally stratified into hormone receptor-positive and 
negative groups to guide patient management. This is because almost all hormone 
antagonist (i.e. tamoxifen)-responsive breast cancers are Estrogen Receptor (ER) and/or 
Progesterone Receptor (PR)-positive1. However, a subgroup of these patients experience 
disease relapse irrespective of standard therapy with tamoxifen2-4. In many cases the 
resistance mechanism(s) are unknown5-7. A method for identifying those ER+ and/or PR+ 
patients that do well in the presence of tamoxifen versus those that do poorly would be of 
significant value. 
Gene expression profiling is a powerful method for breast cancer prognostication. 
Using gene expression profiling, breast tumors can be classified into five molecular 
subtypes (Basal-like, HER2+/ER-, Normal Breast-like, and Luminal A and B) with 
significant differences in patient outcome8,9. The two Luminal subtypes are almost 
entirely composed of ER+ and/or PR+ tumors and are defined by the high expression of a 
gene set (luminal epithelial/ER+ set) that includes ER and GATA3. Compared to Luminal 
A tumors, Luminal B tumors have poor outcomes despite being clinically ER+8,9. 
To date, several laboratories have developed gene expression-based predictors for 
ER+ and/or PR+ patients. All used supervised analyses based upon patient 
outcomes/tumor response10-13. Here we developed a gene expression-based predictor 
using an approach based solely upon biological characteristics of the tumors. Because of 
the importance of estrogen signaling in breast epithelial cell biology, we hypothesized 
that differential expression of estrogen-regulated genes would be useful in predicting 
outcome.  
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MATERIALS AND METHODS 
Cell culture and collection of mRNA. MCF-7 cells were maintained as described 
previously14. Cells were plated in 150mm dishes and grown until 50% confluence.  
Media was changed and cells maintained for 48 hours in estrogen-free medium (phenol 
red-free RPMI-1640 with 10% charcoal-dextran-stripped FBS) before treating for 
2,4,8,or 24 hours with 10-6 M 17β-estradiol (Sigma). Cells were harvested, and mRNA 
isolated using a Micro-FastTrack kit (Invitrogen). A reference mRNA sample was 
harvested from cells maintained for 48 hours in estrogen-free medium (i.e. estrogen-
starved cells). 
 
Microarray Experiments.  Agilent Human whole-genome microarrays were hybridized 
according to manufacturer’s protocol with Cy3-CTP labeled cRNA from estrogen-starved 
cells (2μg/sample) and Cy5-CTP labeled cRNA from 17β-estradiol-treated cells 
(2μg/sample), with dye-flip replicates for each time point. Microarrays were scanned and 
image files analyzed as described previously15. All primary microarray data are available 
via the UNC Microarray Database (https://genome.unc.edu/) and the GEO with series 
number GSE2740 (GSM52882-GSM52909, GSM34423-GSM34568). 
 
Analysis of microarray data to identify GATA3 and estrogen-regulated genes. Data 
from microarray experiments were calculated as described15. Genes were excluded from 
data analysis if they did not have signal intensity ≥30 in both channels for ≥70% of the 
experiments. To identify estrogen-regulated genes, we used one-class Significance 
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Analysis of Microarrays (SAM) to identify genes that changed in all estrogen-treated 
time points (as a single class) relative to the estrogen-starved cells16 (Note: in our SAM 
analyses we did not use the fold-change cutoff option to avoid the fold-change associated 
complications/pitfalls described by Larsson et al.17). Using a false discovery rate (FDR) 
of 0.04%, SAM identified 383 estrogen-induced and 574 estrogen-repressed genes; for 
subsequent “estrogen-SAM” analyses, only the 383 induced genes were used. Average 
linkage hierarchical cluster analysis was conducted and the results visualized in 
Treeview18.  
GATA3-induced genes were identified by microarray experiments on 293T cells 
transfected with GATA3 gene constructs, as detailed in Usary et al.19. One-class SAM 
analysis (0.58% FDR) identified 407 genes that were induced in the GATA3 samples (as 
a single class) relative to empty vector controls. 
 
Analysis of primary breast tumor data using the estrogen-induced gene set. The 
primary breast tumor samples (collected with patient consent and UNC-CH Human 
Investigations Review Committee approval) used in the training dataset are described in 
Hu et al.20, except for 14 new tumor samples. A total of 118 fresh frozen breast tumor 
and 9 normal breast samples represented by 160 microarray experiments were analyzed 
using the 1300-gene “breast intrinsic” gene set developed by Hu et al.20, which identified 
65 tumors as belonging to the “Luminal subtype”. These “Luminal” tumors included 61 
ER+ and/or PR+ tumors according to immunohistochemistry, 3 ER- and PR-, and one not 
determined.  
The 383-gene MCF-7 estrogen-induced gene list was used to hierarchically 
cluster the 65 Luminal tumors resulting in two groups, which we called Groups I and II.  
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We used a two-class, unpaired SAM analysis (with 1% FDR) to identify 822 genes 
(referred to as the estrogen-SAM list) that optimally differentiated Group I versus Group 
II tumors21,22. The 65 Luminal tumors were then clustered using the 822 genes and two 
groups (Groups IE and IIE) were evident. 
By matching Unigene identifiers, data for as many as possible of the 822 
estrogen-SAM genes was obtained for ER+ and/or PR+ tumors (classified as provided in 
the primary publications) from three independent test datasets8,9,12,23. The Ma et al., 
Sorlie et al., and Chang et al. datasets consisted of 60, 90, and 250 ER+ and/or PR+ 
tumors respectively. Ma et al. tumors were uniformly treated with adjuvant tamoxifen 
alone. Sorlie et al. tumors received adjuvant tamoxifen, with some also receiving 
neoadjuvant chemotherapy. Chang et al. tumors were heterogeneously treated 
(http://www.pnas.org/cgi/content/abstract/0409462102v1); 24 of the 250 tumors we used 
for this dataset were published earlier24. 
To remove microarray platform/source systematic biases, we applied Distance 
Weighted Discrimination/DWD25 to the training and test datasets. From the DWD 
standardized Luminal tumor training dataset, centroids were created consisting of the 
average expression of the 822 estrogen-SAM genes for Groups IE and IIE. We then 
classified each ER+ and/or PR+ tumor in the test datasets as Group IE or IIE according to 
each sample’s nearest centroid as determined by Spearman correlation. 
 
Survival Analyses. Kaplan-Meier survival plots were compared using the Cox-Mantel 
log-rank test in Winstat for Excel (R. Fitch Software, Staufen, Germany). Two-way 
contingency table analysis was done using Winstat for Excel. For the Chang et al. 
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dataset, multivariate Cox proportional hazards analysis was performed using SAS (Cary, 
NC).  
 
RESULTS 
Identification of estrogen-regulated genes. To identify estrogen-regulated genes, we 
used the ER+ human breast tumor-derived MCF-7 cell line as a model system.  A “one-
class” SAM supervised analysis16 with an FDR of 0.04% identified 383 induced and 574 
repressed genes in microarray experiments on MCF-7 cells treated with 17β-estradiol for 
2, 4, 8, or 24 hours (hierarchical clustering of these genes is shown in Figure 1). Many 
genes identified were previously known to be ER-regulated including CCND1, PR, 
RERG, CTSD, and PDZK126-29. Using the program EASE30, the Gene Ontology (GO) 
categories “sterol metabolism/biosynthesis”, “ribosome biogenesis/assembly”, and 
“cytoskeleton structural constituent” were over-represented relative to chance in the set 
of 383 estrogen-induced genes. 
 
Estrogen and GATA3-regulated genes are present in the Luminal/ER+ gene cluster. 
The Luminal/ER+ expression cluster is a gene set identified in many breast tumor 
profiling studies24,31-33, includes GATA3 and ER, and is expressed in the Luminal A and B 
tumor subtypes8,9. To determine whether estrogen-regulated genes are present in the 
Luminal/ER+ gene set, we first clustered 118 primary breast tumors using a 1300-gene 
“breast intrinsic” gene set developed by Hu et al.20 (Figure 2). Figure 2B shows that 
many of the estrogen-regulated genes from our in vitro MCF-7 experiments were present 
in the tumor defined Luminal/ER+ gene cluster. To further define relationships among 
genes in this cluster, we also ascertained the presence of genes regulated by GATA3, a 
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transcription factor with an important role in ER+ breast cancer biology19. Of the 407 
genes induced by GATA3 in vitro, many were present in the Luminal/ER+ gene cluster. 
Thus, genes identified as being regulated by ER and/or GATA3 in vitro also cluster near 
these transcription factors in vivo and help to define an expression pattern seen in many 
studies24,31,33,34. 
 
Analysis of Luminal tumors using estrogen-induced genes. We hypothesized that 
expression differences of estrogen-induced genes may define clinically relevant 
subgroups within clinically defined ER+ and/or PR+ tumors. To test this hypothesis, we 
clustered the 65 tumors identified as “Luminal” in Figure 2 (blue dendrogram branch) 
using the 383 MCF-7 estrogen-induced genes. Two main groups resulted (Groups I and 
II). Group I had higher expression of XBP1, PR, and TFF, which are all known ER 
targets. Group II had higher expression of a cluster of estrogen-induced genes that 
included CTPS, E2F6, and FANCA. Kaplan-Meier survival analysis showed that Group I 
patients had significantly better Relapse-Free Survival (RFS) outcomes than Group II 
(p=0.0004). 
To further characterize the differences between Group I and II tumors, we 
performed a supervised analysis (2-class SAM with 1% FDR) using the major 
dendrogram branch division that separated Group I and II tumors to define the two 
supervising groups. This analysis identified 822 genes for which Group I and II tumors 
showed significant differential expression. This gene set, called the “estrogen-SAM” list, 
was then used to hierarchically cluster the 65 Luminal tumors (Figure 3), which as 
expected, resulted in a very similar grouping of samples when compared to that using the 
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383 estrogen-induced genes. Kaplan-Meier analysis showed that using the estrogen-SAM 
list grouped the tumors into two groups (referred to as Group IE and IIE) that predicted 
RFS (p=0.019, Figure 4A).  
Group IE tumors showed high expression of XBP1, FOXA1, PR and many 
ribosomal genes (Figure 3B-E). According to EASE, the GO categories “transcriptional 
regulation”, “DNA binding”, and “extracellular” were over-represented relative to chance 
in Group IE tumors. Group IIE tumors showed the high expression of a prominent 
proliferation signature35,36 including Ki-67, MYBL2, Survivin, STK6, and CCNB2 (Figure 
3G); these first four genes plus CCNB1 form the basis for the proliferation portion of the 
Paik et al. “Recurrence Score” predictor13, which is a gene expression-based outcome 
predictor for ER+/node-negative, tamoxifen-treated patients. Recently Dai et al. 
performed a supervised analysis for genes that correlated with outcomes in patients with 
high ER expression relative to age and identified this same proliferation signature as the 
main determinant for predicting patient outcomes10; however, they identified few genes 
associated with good outcomes. 
Group IIE tumors also showed high expression of a cluster of MAGE-A genes 
(Figure 3F), which have been associated with an increased recurrence risk37 and poor 
tumor differentiation38. Figure 3H shows Group IIE tumors have high expression of 
genes with functions in the Interferon-pathway and apoptosis such as FLIP/CFLAR, 
which is an inhibitor of TNFR-mediated apoptosis39. Several anti-apoptosis genes 
including FLIP, AVEN, Survivin and BCL2A1 showed high expression in Group IIE, 
suggesting an impaired ability to undergo cell death. Recent reports have shown that high 
expression of FLIP40 or BCL2A141,42 can directly contribute to chemoresistance, 
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suggesting that functional inhibition of these proteins may provide a therapeutic target for 
Group IIE patients. According to EASE, the GO categories “cell cycle/mitosis”, “anti-
apoptosis”, and “MHC-I” were over-represented relative to chance in Group IIE.  
 
Group IE-IIE classification predicts outcome in ER+ and/or PR+ tumors. To test the 
Group IE-IIE classification as a clinically relevant outcome predictor, we analyzed ER+ 
and/or PR+ tumors from 3 published breast tumor microarray datasets9,12,23. We used a 
Single Sample Prediction algorithm to classify tumors in each test dataset, which 
involved creating Group IE and IIE centroids/average profiles from the training dataset 
(see Methods). Kaplan-Meier analysis (Figure 4B-D) showed that Group IE tumors had 
significantly better RFS in all test datasets. Figure 5 shows that the Group IE-IIE 
classification was also a significant predictor of Overall Survival (OS) for the test 
datasets in which OS data was available9,23. Furthermore, by decreasing the FDR in 
SAM, we were able to define Groups IE and IIE using a reduced estrogen-SAM list of 
113 genes without any loss of predictive ability (Table 1).  
 
Multivariate analysis. Multivariate Cox proportional hazards analysis was performed on 
the Chang et al. dataset (Table 2). Using RFS and OS as the endpoints, multivariate 
analysis showed that classifying tumors as Group IE or IIE provided significant 
prognostic power independent of standard clinical factors (p<0.0001 using RFS, p=0.001 
using OS). The Group IE-IIE designation had the strongest association of all variables 
with RFS and OS.  
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In multivariate analyses that included Chang et al.’s23 “wound-response” 
signature and van’t Veer et al.’s24 “70-gene signature” along with the clinical variables, 
the Group IE-IIE classification continued to provide significant prognostic power 
independent of other variables in the model (p=0.014 using RFS, p=0.042 using OS, 
Table 3). The performance of the 70-gene and wound-response signatures in this 
multivariate analysis may be optimistically high because a subset of the patients in the 
Chang et al. dataset was used to train/optimize these two signatures; therefore, the ability 
of the Group IE-IIE classification to show independent prognostic power in a model 
containing these two predictors indicates its usefulness in predicting outcomes. 
 
Group IE-IIE associations with clinical and biological parameters. To examine the 
hypothesis that Group IE may be more differentiated than Group IIE tumors, we 
determined whether an association existed between this classification and histological 
grade. Two-way contingency table analysis showed significant association between grade 
and Group IE-IIE class (Table 4), with grade 1 and 3 tumors more likely to be classified 
as Group IE and IIE, respectively. Cramer’s V statistic, which measures the strength of 
association between two variables in a contingency table, indicated a substantial 
association (Cramer’s V>0.36) between grade and Group IE-IIE class for all datasets. For 
the Sorlie et al. dataset, p53 mutation data was available and a two-way contingency table 
analysis showed a significant association between p53 status and Group IE-IIE class, 
with Group IIE more likely to be p53 mutant (p=0.0019; Cramer’s V=0.44). 
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Comparison of the Group IE-IIE classification to the Luminal A-B classification. 
We compared the Group IE-IIE classification to the Luminal A-B classification8,9. To 
identify Luminal A and B tumors in the three test datasets, we used the Single Sample 
Predictor developed in Hu et al.20, which employs centroids for each of the five breast 
tumor “intrinsic subtypes”. We then reclassified Luminal A and B tumors from each 
dataset as Group IE or IIE. Kaplan-Meier analyses showed that the Group IE-IIE 
classification did equally well or slightly better than the Luminal A-B classification in 
separating Luminal tumors into two groups with different survival outcomes (Table 5). 
 
DISCUSSION 
The search for markers that predict long-term outcomes in hormone receptor-
positive tamoxifen-treated patients has been an intense area of study. Genomic analyses 
have contributed to this area, with the development of several predictive gene sets and 
assays based upon the selection of genes that directly correlate with patient/tumor 
outcomes10-13,24. We took a different approach and selected genes using no knowledge of 
outcomes and instead, selected genes based upon regulation by estrogen and their natural 
patterns of expression in primary tumors. The 822-gene estrogen-SAM list identified 
many genes that may help explain the outcome differences seen in ER+ and/or PR+ 
patients. Good outcome group IE tumors tended to be more differentiated and highly 
expressed a subset of estrogen and GATA3-regulated genes. Conversely, poor outcome 
Group IIE tumors were more likely to be poorly differentiated. Association of the Group 
IE-IIE profile with grade is expected because grade includes a measure of proliferation, 
which is an important determinant of outcomes in ER+ and/or PR+ patients8,10,13,19. 
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However, because the Group IE-IIE distinction was significant in a multivariate analysis 
with grade included, this distinction adds prognostic information beyond what grade 
provides. 
We used three published datasets as test sets and confirmed that the Group IE-IIE 
classification was a significant predictor in ER+ and/or PR+ patients. We note, however, 
that the relapse rates differed between datasets and that the Group IE tumors showed 7-
40% relapse rates depending on the dataset (Figure 4). This underscores the fact that 
relapse rates are dependent upon the characteristics of the patient set used. For example, 
comparing relapse rates in the Chang et al. dataset to those observed in Paik et al. may 
not be valid because the Paik et al. dataset was comprised of tamoxifen-treated node-
negative patients, while the majority of the Chang et al. patients received no adjuvant 
therapy and many were node-positive. However, the multivariate analysis we performed 
on the Chang et al. dataset indicated that our predictor had significant prognostic value 
independent of standard clinical factors and other gene expression-based predictors, and a 
hazard ratio of 2.90 for Group IIE vs. IE indicates our predictor has potential clinical 
utility. By limiting the Chang et al. dataset to those patients who received adjuvant 
therapy and were Stage I+II, we observed a relapse rate for Group IE patients of 12% 
(Figure 5D, p=0.007) and significance for overall survival outcomes (data not shown). 
This indicates that given a patient population similar to Paik et al., our predictor’s “good 
group” can achieve outcomes similar to the Paik et al. “Low Risk” group. 
An important unanswered question is whether the Group IE-IIE distinction 
predicts pure prognosis, responsiveness to endocrine therapy, or both. From analyses of 
patient subsets in the Chang et al. dataset, it is clear that the Group IE-IIE distinction 
  
 30 
predicts outcome in ER+ and/or PR+ patient subsets either receiving or not receiving 
adjuvant hormone therapy (data not shown). Paik et al. observed similar results for their 
predictor13. This is not surprising because half (8/16) of the Paik et al. genes were present 
in the “estrogen-SAM” gene set. However, an advantage of our analysis is that it provides 
additional biological information (e.g. anti-apoptosis genes) that the Paik et al. and other 
predictors did not. Paik et al.’s finding that their predictor also predicts benefit of 
chemotherapy43 may also apply to ours. Thus, the most pressing questions remaining 
regarding the Group IE-IIE classification are (1) whether Group IE and IIE gain similar 
benefits from chemotherapy, and (2) because Group IIE tumors do poorly in the presence 
of tamoxifen, might they do better if given alternative endocrine therapies. 
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TABLES 
 
Table 2.1. Summary of Kaplan-Meier Relapse-Free Survival analyses performed for each 
tumor dataset using the estrogen-induced or estrogen-SAM gene lists. 
 
  Training   Testing  
 
 
 
Gene list 
 Luminals 
 
(65 tumors, 
10 events) 
 
Ma et al.  
ER+ and/or 
PR+  
(60 tumors,  
28 events) 
Sorlie et al. 
ER+ 
and/or PR+
(90 tumors,  
45 events) 
Chang et al. 
ER+ and/or 
PR+ 
(250 tumors, 
86 events) 
383 estrogen- 
induced gene 
list 
 
p=0.0004 0.044  
 
0.0008 
 
 
8.1e-5 
 
822 gene 
estrogen-SAM 
list 
 
0.019 0.0006 
 
0.0007 
 
1.3e-5 
 
113 gene  
reduced 
estrogen-SAM 
list 
 
0.007 
 
0.008 
 
0.001 
 
6.6e-6 
 
Each cell in the table contains the p-value calculated using the log-rank test for the 
Kaplan-Meier relapse-free survival curves produced for the two tumor groups identified 
by each gene list in each tumor dataset. p-values <0.05 are in bold.  
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Table 2.2. Multivariate Cox proportional hazards analysis of various prognostic factors 
in relation to Relapse-Free Survival and Overall Survival for ER+ and/or PR+ tumors in 
the Chang et al. (2005) dataset. 
 
    Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
 
Group IIE vs. IE 
 
Age, per decade 
 
Size 
 
Tumor grade 2,3 vs. 1 
 
Node status  
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
 
 
2.90 (1.71-4.92) 
0.48 (0.31-0.74) 
1.59 (1.01-2.48) 
1.80 (0.99-3.3) 
 
2.11 (1.08-4.11) 
0.36 (0.18-0.71) 
 
 
<0.0001 
 
0.001 
 
0.044 
 
0.056 
 
0.028 
 
0.003 
 
 
 
3.64 (1.67-7.95) 
0.53 (0.30-0.93) 
1.45 (0.80-2.64) 
 
3.57 (1.24-10.23) 
1.85 (0.74-4.61) 
 
0.47 (0.19-1.19) 
 
 
0.001 
 
0.028 
 
0.22 
 
0.02 
 
0.19 
 
0.11 
 
Size was a binary variable (0= diameter of 2cm or less, 1= greater than 2cm); node status 
was a binary variable (0= no positive nodes, 1= one or more positive nodes); age was a 
continuous variable formatted as decade-years. Tumors were classified as Group IE or 
IIE using the estrogen-SAM derived list. Variables found to be significant (p<0.05) in the 
Cox proportional hazards model are shown in bold.  
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Table 2.3. Multivariate Cox proportional hazards analysis for ER+ and/or PR+ tumors in 
the Chang et al. (2005) dataset using various prognostic factors including the Group IE-
IIE classification, the van’t Veer et al. (2002) 70-gene signature, and the Chang et al. 
(2005) Wound-Response signature. 
  
    Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
 
Group IIE vs. IE 
 
70-gene signature (poor vs. 
good) 
 
Wound-response signature 
(activated vs. quiescent) 
 
Age, per decade 
 
Size 
 
Tumor grade 2,3 vs. 1 
 
Node status  
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
 
 
2.01 (1.15-3.49) 
 
2.76 (1.50-5.06) 
 
 
2.30 (1.09-4.85) 
 
 
0.56 (0.36-0.87) 
 
1.45 (0.93-2.28) 
 
0.93 (0.47-1.82) 
 
1.72 (0.89-3.33) 
 
0.37 (0.19-0.74) 
 
 
0.014 
 
0.001 
 
 
0.028 
 
 
0.010 
 
0.10 
 
0.82 
 
0.11 
 
0.005 
 
 
2.31 (1.03-5.19) 
4.17 (1.62-10.73) 
 
2.80 (0.82-9.55) 
 
 
0.64 (0.36-1.14) 
 
1.34 (0.74-2.45) 
 
1.62 (0.53-4.93) 
 
1.51 (0.62-3.70) 
 
0.46 (0.18-1.14) 
 
 
0.042 
 
0.003 
 
 
0.10 
 
 
0.13 
 
0.34 
 
0.40 
 
0.36 
 
0.095 
 
Tumor size, node status, age, and Group IE-IIE were defined as in Table 1. The 70-gene 
signature and the wound-response signature classifications were taken exactly as 
calculated in Chang et al. (2005), and their performances in multivariate analysis may be 
optimistic. Variables found to be significant (p<0.05) in the Cox proportional hazards 
model are shown in bold.  
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 Table 2.4. Association between tumor grade and the Group IE-IIE classification 
(estrogen-SAM derived list).   
 
                
 
 
65 luminal 
tumors from 
training set 
 
 
Ma et al. 
ER+/PR+ 
tumors 
 
 
Sorlie et al. 
ER+/PR+ 
tumors 
 
 
Chang et al. 
ER+/PR+ 
tumors 
 
 
       Group 
  IE          IIE 
 
(# of patients) 
     
      Group 
  IE        IIE 
 
(# of patients) 
     
      Group 
  IE       IIE 
 
(# of patients) 
 
      Group 
  IE      IIE 
 
(# of patients) 
Two-way 
contingency table 
 
 
Histologic grade    
 
        1 (well) 
        2 (intermediate) 
        3 (poor)  
 
11 
16 
9 
 
0 
12 
14 
 
3 
29 
6 
 
0 
10 
12 
 
10 
32 
16 
 
0 
11 
20 
 
50 
46 
13 
 
24 
49 
64 
Statistics for two-
way contingency 
table analysis  
 
p-value† 
 
Cramer’s V†† 
 
 
 
 
 
0.003 
 
0.43 
 
 
 
 
0.005 
 
0.42 
 
 
 
 
0.001 
 
0.39 
 
 
 
 
1.7e-9 
 
0.40 
† p-value calculated from Chi-square test on contingency table. †† Cramer’s V statistic 
(value can range from 0 to 1) measures the strength of association between the two 
variables analyzed in the contingency table, with 1 indicating perfect association and 0 
indicating no association.  
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Table 2.5. Comparison of the Group IE-IIE classification to the Luminal A-B 
classification in predicting RFS for three datasets of Luminal epithelial tumors. 
 
†When the Kaplan-Meier disease-specific survival curves were compared, the Group IE-
IIE classification scheme showed significantly different survival curves (p=0.031) 
whereas the Luminal A-B classification scheme did not (p=0.17).  
 
 
 
 
Classification 
method 
 
Survival analysis 
statistic 
Ma et al. 
(43 tumors, 
20 events) 
Sorlie et al. † 
(57 tumors, 20 
events) 
Chang et al. 
(194 tumors, 
62 events) 
Luminal A-B 
classification  
 
p-value 
 
Hazard ratio of B vs. A 
(95% CI) 
p=0.011 
                       
HR=3.1 (0.9- 10.6) 
0.14 
 
1.9 (0.7- 5.0)  
1.1e-9 
 
4.2 (2.4-7.5) 
Group I-II 
classification  
 
p-value 
 
Hazard ratio of II vs. I 
(95% CI) 
0.0002 
                            
4.9 (1.8- 13.0)  
0.076 
 
2.2 (0.8-5.8)  
1.3e-6 
 
4.0 (2.4-6.6)  
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FIGURES 
 
 
Figure 2.1. Hierarchical clustering analysis of the genes determined by 1-class SAM to 
be estrogen-induced (383 genes) or estrogen-repressed (574 genes). A. Scaled-down 
representation of the complete cluster diagram. B, C. Subsets of estrogen-induced genes 
with known estrogen-induced genes highlighted in red. For each gene, mRNA levels at 
the indicated time point are relative to the estrogen (E2)-starved control sample. 
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Figure 2.2. Genes regulated by estrogen and/or GATA3 in vitro are present in the 
primary tumor Luminal epithelial/ER+ gene cluster. A. Scaled-down representation of 
118 tumors hierarchically clustered using the 1300-gene intrinsic list developed by Hu et 
al.20 B. Luminal/ER+ gene cluster. The tumor sample dendrogram is colored as: 
blue=Luminal epithelial subtype, pink=HER2+/ER-, red=Basal-like, and green=Normal 
Breast-like.
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Figure 2.3. Hierarchical cluster analysis of the 65 Luminal tumors (identified in Figure 
2.1) using the 822-gene estrogen-SAM derived list. A. Scaled-down representation of the 
complete cluster diagram. Group IE and IIE tumors are indicated by blue and orange, 
respectively. Gene clusters containing B. XBP1, C. Ribosomal genes, D. Progesterone 
receptor, E. FOXA1, F. MAGE genes, G. Proliferation signature, and H. Apoptosis and 
interferon-response genes. 
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Figure 2.4. Kaplan-Meier survival curves of ER+ and/or PR+ tumors classified as 
Groups IE or IIE using the 822-gene estrogen-SAM derived list. Survival curves are 
shown for A. the 65 Luminal epithelial tumor training dataset, B. the Ma et al., C. Sorlie 
et al., and D. Chang et al. datasets. p-values calculated using the log-rank test. 
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Figure 2.5. Kaplan-Meier Overall Survival curves of tumors classified into Groups IE 
and IIE using the 113-gene estrogen-SAM derived list. Overall survival curves are shown 
for A. the Sorlie et al. and C. Chang et al. data sets. Disease specific survival curves are 
shown for B. the Sorlie et al. dataset. D. Relapse-free survival curves for Chang et al. 
Stage I + II patients only. p-values were calculated using the log-rank test. 
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ABSTRACT 
Background 
Validation of a novel gene expression signature in independent data sets is a critical step 
in the development of a clinically useful test for cancer patient risk-stratification. 
However, validation is often unconvincing because the size of the test set is typically 
small. To overcome this problem we used publicly available breast cancer gene 
expression data sets and a novel approach to data fusion, in order to validate a new breast 
tumor intrinsic list. 
 
Results 
A 105-tumor training set containing 26 sample pairs was used to derive a new breast 
tumor intrinsic gene list. This intrinsic list contained 1300 genes and a proliferation 
signature that was not present in previous breast intrinsic gene sets. We tested this list as 
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a survival predictor on a data set of 311 tumors compiled from three independent 
microarray studies that were fused into a single data set using Distance Weighted 
Discrimination. When the new intrinsic gene set was used to hierarchically cluster this 
combined test set, tumors were grouped into LumA, LumB, Basal-like, HER2+/ER-, and 
Normal Breast-like tumor subtypes that we demonstrated in previous datasets. These 
subtypes were associated with significant differences in Relapse-Free and Overall 
Survival. Multivariate Cox analysis of the combined test set showed that the intrinsic 
subtype classifications added significant prognostic information that was independent of 
standard clinical predictors. From the combined test set, we developed an objective and 
unchanging classifier based upon five intrinsic subtype mean expression profiles (i.e. 
centroids), which is designed for single sample predictions (SSP).  The SSP approach 
was applied to two additional independent data sets and consistently predicted survival in 
both systemically treated and untreated patient groups. 
 
Conclusions  
This study validates the “breast tumor intrinsic” subtype classification as an objective 
means of tumor classification that should be translated into a clinical assay for further 
retrospective and prospective validation.  In addition, our method of combining existing 
data sets can be used to robustly validate the potential clinical value of any new gene 
expression profile. 
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INTRODUCTION 
The classification of human tumors using microarray data has been an area of 
intense research, but it remains a daunting task to validate a new profile and generate a 
clinically useful test. Many different gene expression-based predictors have been 
developed for breast cancer1-9, and two different gene expression predictors have reached 
the final step of prospective clinical trial testing10,11. Using cDNA microarrays, we 
previously identified five distinct subtypes of breast tumors arising from at least two 
distinct cell types (basal-like and luminal epithelial cells)1-3. This molecular taxonomy 
was based upon an “intrinsic” gene set, which was identified using a supervised analysis 
to select genes that showed little variance within repeated samplings of the same tumor, 
but which showed high variance across tumors1. We showed that an intrinsic gene set 
reflects the stable biological properties of tumors and typically identifies distinct tumor 
subtypes that have prognostic significance, even though no knowledge of outcome was 
used to derive this gene set3,12-14.   
A major challenge for microarray studies, especially those with clinical 
implications, is validation15,16. Due to the practical barriers of cost and access to large 
numbers of fresh frozen tumor samples with associated clinical information, very few 
microarray studies have analyzed enough samples to allow promising initial findings to 
be sufficiently validated to justify the major investment required for clinical testing. An 
efficient approach would be to use public gene expression data repositories as test sets; 
however, it has been difficult to compare and/or combine data sets from independent 
laboratories due to differences in sample preparation, experimental design, and 
microarray platforms. An accepted method for validation is to derive a 
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prognostic/predictive gene set from a “training set” and then apply it to a completely 
independent “test set”17.  The “purest” test sets are comprised of samples not generated 
by the primary investigators to remove any possibility of bias18. In this study, we 
illustrate the successful application of these principles by (1) deriving a new breast tumor 
intrinsic gene list that identifies the “intrinsic” biological features of breast tumors and 
(2) validating this predictor using a combined test set of 311 breast tumor samples 
compiled from the public domain. These analyses show that the breast tumor intrinsic 
subtypes are significant predictors of outcome when correcting for standard clinical 
parameters, and that common patterns of expression and outcome predictions can be 
identified in data sets generated by independent labs. 
 
MATERIALS AND METHODS 
Sample collection, RNA isolation and microarray hybridization. 105 fresh frozen 
breast tumor samples and 9 normal breast samples were obtained using IRB-approved 
protocols at 4 institutions: the University of North Carolina at Chapel Hill (UNC-CH), 
The University of Utah, Thomas Jefferson University, and the University of Chicago. 
This sample set represents an ethnically and geographically diverse cohort. Patients were 
heterogeneously treated according to the standard of care dictated by disease stage, ER 
and HER2 status.  
Total RNA was purified from each sample using the Qiagen RNAeasy Kit. RNA 
integrity was determined using the RNA 6000 Nano LabChip Kit and Agilent 2100 
Bioanalyzer. Total RNA amplification and labeling were done as previously described35. 
Microarray hybridizations were performed using Agilent Human oligonucleotide (1Av1, 
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1Av2 and custom designed 1Av1-based) microarrays using 2μg of Cy3-labeled common 
reference sample that is a modified version of the Stratagene Human Universal 
Reference36, and 2μg of Cy5-labeled experimental sample. Microarrays were hybridized 
overnight, washed, dried, and scanned as described35. The image files were analyzed with 
GenePix Pro 4.1 and loaded into the UNC-CH Microarray Database 
(https://genome.unc.edu/) where a Lowess normalization procedure was performed to 
adjust the Cy3 and Cy5 channels37. All primary microarray data associated with this 
study are available at https://genome.unc.edu/pubsup/breastTumor/ and in the GEO 
(http://www.ncbi.nlm.nih.gov/geo/) under the accession number of GSE1992, series 
GSM34424-GSM34568. 
 
Identification of the Intrinsic gene set. We derived a new breast tumor intrinsic gene 
set, referred to as the “Intrinsic/UNC” list, using a training set composed of the 105 
tumor samples described above, 9 normal breast samples, and 26 sample pairs (in total, 
represented by 146 microarrays). 15, 9, and 2 of the 26 sample pairs were different 
physical pieces of the same tumor (taken at the same time point), tumor-metastasis pairs 
and normal sample pairs, respectively. The background subtracted, Lowess normalized 
log2 ratio of Cy5 to Cy3 intensity values were first filtered to select genes that had a 
signal intensity of at least 30 units above background in both the Cy5 and Cy3 channels. 
Only genes that met these criteria in at least 70% of the 146 microarrays were included 
for subsequent analysis. Next, we performed an “intrinsic” analysis as described 
previously3 using the 26 sample pairs and 86 additional microarrays. An intrinsic analysis 
identifies genes showing low variability in expression within paired samples but high 
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variability in expression across different tumors; for each gene a ratio of “within-pair 
variance” to “between-subject variance” is computed. Genes with ratios below one 
standard deviation of the mean ratio were defined as “intrinsic”. This analysis resulted in 
1410 microarray elements representing 1300 genes being identified as “intrinsic”. In 
order to obtain an estimate of the number of false-positive intrinsic genes, we permuted 
the sample labels to generate 26 random pairs and 86 non-paired samples. This 
permutation was performed 100 times and the intrinsic scores were calculated for each. 
These permuted scores were used to determine a threshold on the intrinsic score 
corresponding to a false discovery rate (FDR) less than 1%. The selected threshold 
resulted in 1410 microarray features being called significant with a median FDR=0.3% 
and 90th percentile FDR=0.5%. (See Tusher et al. for a complete description of this 
calculation38). 
 
Creation and analyses of the combined test set. The independent test set was a 315-
sample “combined test set” consisting of three DNA microarray datasets (Sorlie et al. 
2001 and 20032,3, van’t Veer et al. 20025 and Sotiriou et al. 200319). To combine these 
datasets obtained from different microarray platforms, we performed the following pre-
processing methods. First, the R/G ratios in each dataset were log2 transformed and 
Lowess normalized37. Next, missing values were k-NN imputed39. Gene annotations from 
each dataset were converted into UniGene Cluster IDs (UCIDs, Build 161) using the 
SOURCE database40, and multiple occurrences of a UCID were collapsed by taking the 
median value for that ID within each experiment and platform, which resulted in ~2800 
genes having expression data in all three datasets. Next, Distance Weighted 
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Discrimination20 was performed in a pair-wise fashion by first combining the Sorlie et al. 
and Sotiriou et al. datasets, and then combining this with the van’t Veer et al. dataset to 
make a single dataset. In the final pre-processing step, each microarray experiment was 
normalized such that each column/experimental sample was standardized to N(0,1), and 
each row/gene was median centered. 306 of the 1300 Intrinsic/UNC genes had 
microarray data present in the combined test set and were used in a two-way average-
linkage hierarchical cluster analysis41. Cluster results were visualized using the program 
“Treeview”. 
 
Derivation of the Single Sample Predictor. The Single Sample Predictor (SSP) is a 
Nearest Centroid-based method based upon the work of Hastie and Tibshirani3,42,43. Our 
SSP classifies an individual sample according to its nearest centroid as determined by 
Spearman correlation. To derive our SSP, we utilized the 315-sample combined test set 
from Figure 2 to create centroids for each of the five intrinsic subtypes (LumA, LumB, 
HER2+/ER-, Basal-like and Normal Breast-like). Please note that we did not create a 
centroid for the IFN group because it failed significance in multivariate testing, but did 
create a centroid for the Normal Breast-like group because we feel it is important to be 
able to identify true normal samples; an H&E examination of most tumor samples falling 
into the Normal Breast-like category shows that this is occurring mainly because of too 
much normal tissue contamination. 
  To create each intrinsic subtype centroid, we averaged the gene expression 
profiles for samples clearly assigned to each subtype (limiting the analysis to 249 of the 
315 samples) using the hierarchical clustering dendrogram as a guide (Figure 2). We then 
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applied the SSP to two independent test datasets: (1) the Ma et al. 60-sample ER+ 
tamoxifen-treated tumor dataset and (2) the Chang et al. 96-sample local only-treated 
tumor dataset. By matching UCIDs, microarray data for as many as possible of the 306 
Intrinsic/UNC genes was obtained from these 2 datasets. To remove microarray 
platform/source systematic biases, we applied DWD to the 2 test datasets relative to the 
combined test set. The SSP was then used to classify tumors by intrinsic subtype in these 
2 test datasets. Using similar methods, the SSP was also applied to the 105-sample 
training set used to derive the intrinsic/UNC gene set. 
 
Survival analyses. Kaplan-Meier survival plots were compared using the Cox-Mantel 
log-rank test in WinSTAT for Excel (R. Fitch Software). Two-way contingency table 
analysis and unpaired Student’s t-test were done using WinSTAT. For the “combined test 
set”, multivariate Cox proportional hazards analysis was performed using SAS (Cary, 
NC).  
 
RESULTS 
Identification of the Intrinsic/UNC gene set. Our goals were to (1) create a new breast 
tumor intrinsic list, (2) validate this list on an independent dataset to show the clinical 
significance of the “intrinsic” classifications, and (3) to derive an objective “intrinsic 
subtype” classifier that could be used clinically (see Figure 1 for overview of analyses 
performed). An intrinsic analysis is a “within class” versus “across classes” analysis that 
identifies genes that show low variability within a group (i.e. a tumor-metastasis pair), 
but which show high variation in expression across different tumors; in essence, one is 
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selecting for genes that are consistently expressed when individual tumors are examined, 
but that vary in expression across different tumors. To develop a new breast tumor 
intrinsic gene set (Intrinsic/UNC), we assayed a training set of 105 breast tumor samples 
and 9 normal breast samples, which contained 26 sample pairs (146 microarray 
experiments in total), using Agilent oligo microarrays. Using the intrinsic analysis 
method as described in Sorlie et al. 20033, we identified an intrinsic gene set of 1410 
microarray elements representing 1300 genes. We felt it important to create a new 
intrinsic list because first, we wanted to take advantage of newer microarrays (Agilent 
arrays with 17,000 genes vs. 8,000 gene cDNA microarrays previously used3), and 
second, we wanted to use paired tumor samples that were not before-and-after 
chemotherapy pairs, but were instead pre-treatment tumor pairs. The Intrinsic/UNC gene 
set showed overlap with a previous breast tumor intrinsic gene set (108 genes in common 
with the Intrinsic/Stanford gene set of Sorlie et al. 20033), but also showed a significant 
increase in gene number likely due to the greater number of genes present on current 
microarrays.  
 
Validation of the Intrinsic/UNC gene list. To evaluate the Intrinsic/UNC gene set on an 
independent test dataset, we applied it to a “combined test set” of 315 breast samples 
(311 tumors and 4 normal breast samples) using hierarchical clustering methods as have 
been done previously1-3. The “combined test set” of 315 breast samples was a single data 
set created by combining together the data from Sorlie et al. 2001 and 2003 (cDNA 
microarrays)2,3, van’t Veer et al. 2002 (custom Agilent oligo microarrays)5 and Sotiriou 
et al. 2003 (cDNA microarrays)19. We created a single data table of these three sets by 
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first identifying the common genes present across all three microarray data sets (2800 
genes). Next, we used Distance Weighted Discrimination (DWD) to combine these three 
data sets together20. DWD is a multivariate analysis tool that is able to identify systematic 
biases present in separate data sets and then make a global adjustment to compensate for 
these biases; in essence, each separate data set is a multi-dimensional cloud of data 
points, and DWD takes two points clouds and shifts one such that it more optimally 
overlaps the other. Finally, we determined that 306 of the 1300 unique Intrinsic/UNC 
genes were present in the combined test set and performed a hierarchical clustering 
analysis of these 306 genes and 315 samples (Figure 2). We analyzed the combined test 
set instead of analyzing each of the 3 datasets separately because we believed this would 
provide more statistical power to perform multivariate analysis, and would yield more 
meaningful results because any finding would need to be shared/present across all 3 
datasets. Remarkably, despite the loss of genes in the Intrinsic/UNC list due to the 
requirement of having to be present on 4 different microarray platforms, the hierarchical 
clustering analysis in Figure 2 identified the five main subtypes/groups corresponding to 
the previously defined HER2+/ER-, Basal-like, LumA, LumB and Normal Breast-like 
tumor groups2,3. 
As shown in previous studies, a HER2+ expression cluster was observed in the 
cluster analysis of the “combined test set” and contained multiple genes from the 17q11 
amplicon including HER2/ERBB2 and GRB7 (Figure 2D). The HER2+ intrinsic subtype 
(pink dendrogram branch in Figure 2B) was predominantly ER-negative (i.e. HER2+/ER-
) as previously shown. A Basal-like expression cluster was also present and contained 
genes (i.e. c-KIT, FOXC1 and P-Cadherin) previously identified to be characteristic of 
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basal epithelial cells (Figure 2F). Using the program EASE21, the Gene Ontology (GO) 
categories “extracellular space” and “extracellular region” were over-represented relative 
to chance in the Basal epithelial gene cluster. As shown in previous studies, a 
Luminal/ER+ expression cluster was present and contained ER, XBP1, FOXA1 and 
GATA3 (Figure 2C). GATA3 has recently been shown to be somatically mutated in some 
ER+ breast tumors, and some of the genes in Figure 2C are GATA3-regulated (FOXA1 
and TFF3)22, thus showing the functional clustering of a transcription factor and some of 
its direct targets. The Gene Ontology (GO) categories “transcription regulator activity” 
and “DNA binding” were over-represented relative to chance in the Luminal/ER+ gene 
cluster.  
The most significant difference between the previous Intrinsic/Stanford gene lists 
and the new Intrinsic/UNC gene list was that the latter contained a large proliferation 
signature (Figure 2G)23-25. As expected, EASE analysis showed that the GO categories 
“mitotic cell cycle” and “M phase” were over-represented relative to chance in the 
proliferation signature. The inclusion of proliferation genes in the Intrinsic/UNC gene set, 
but not in the Intrinsic/Stanford gene set, is likely due to the fact that the 
Intrinsic/Stanford lists were based upon before-and-after chemotherapy paired samples of 
the same tumor, while the Intrinsic/UNC list was based upon paired samples taken at the 
same time point with respect to chemotherapy (22/26 were pre-treatment pairs). This 
finding suggests that tumor cell proliferation rates do vary before and after 
chemotherapy, but that proliferation is a reproducible and intrinsic feature of a tumor’s 
expression profile.  
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A possible new tumor group (IFN) characterized by the high expression of 
Interferon (IFN)-regulated genes was observed in the combined test set analysis (Figure 
2E). According to EASE, the GO categories “immune response” and “defense response” 
were over-represented relative to chance in the interferon-regulated gene cluster. This 
cluster contained STAT1, which is thought to be the transcription factor responsible for 
mediating IFN-regulation of gene expression26,27. Genes in the IFN cluster have been 
linked to lymph node metastasis and poor prognosis7,13. In summary, the Intrinsic/UNC 
list contained more genes than previous lists, encompasses most features of the 
Intrinsic/Stanford list (i.e. Basal, Luminal/ER+, and HER2-amplicon gene clusters) and 
adds the biologically and clinically relevant proliferation signature.  
 
Tumor subtypes identified by the Intrinsic/UNC gene set are predictive of outcome. 
To determine how many biologically relevant tumor subtypes/groups might be present 
within the cluster in Figure 2, we used 3 criteria, which resulted in the identification of 6 
potential subtypes/groups. The first criteria was the simple and obvious dendrogram 
branching pattern (Figure 2B) suggesting six groups. Second was the observation that 
each of the six groups uniquely expressed distinct sets of known biologically relevant 
genes including the basal, luminal/ER+, HER2-amplicon, IFN-regulated, and 
proliferation-associated signatures. Third was our knowledge of the previous 
classifications made by the Sorlie et al. 2003 Intrinsic/Stanford list of the 
Stanford/Norway samples: there was a high concordance (78%) between the 
classification of these samples made using either the Sorlie et al. 2003 Intrinsic/Stanford 
list or the Intrinsic/UNC list (excluding the IFN samples). Therefore, the 311 
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tumors/patients were stratified into six groups, and we proceeded to look for differences 
in outcomes and associations with other clinical parameters between these six groups. 
The Intrinsic/UNC gene set identified tumor groups/subtypes that were predictive of 
Relapse-Free Survival (RFS, Figure 3A) and Overall Survival (OS, p=0.000001, data not 
shown) in Kaplan-Meier survival analysis on the combined test set. As previously seen in 
Sorlie et al.2,3, the LumA group had the best outcome while the HER2+/ER-, Basal-like, 
and LumB groups had significantly worse outcomes. The new IFN class had a Kaplan-
Meier survival curve similar to that of LumB, and both showed elevated proliferation 
rates when compared to LumA (Figure 2G).  
In the combined test set, the standard clinical parameters of ER status, node 
status, grade, and tumor size (note: data for clinical HER2 status was not available) were 
significant predictors of RFS using Kaplan-Meier analysis (Figure 4), thus showing that 
the act of combining three different patient sets together did not destroy the prognostic 
abilities of these standard markers. In a multivariate Cox proportional hazards analysis of 
the combined test set using these standard clinical parameters, size, grade and ER status 
were significant predictors of RFS (Table 1A).  
To further evaluate the prognostic/predictive value of the intrinsic subtype 
classification, we performed multivariate Cox proportional hazards analysis of the 
combined test set using the six intrinsic subtypes/groups defined above and the five 
standard clinical parameters with RFS, OS, or DSS as the endpoint (Table 1B shows 
analysis for RFS). The intrinsic subtypes, when added to the multivariate model 
containing the standard clinical variables, resulted in a model significantly more 
predictive of RFS, OS, and DSS (p=0.01, 0.009, and 0.04 respectively, by the likelihood-
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ratio test). In multivariate analysis for RFS (Table 1B), the Basal-like, LumB and 
HER2+/ER- subtypes had hazard ratios significantly greater than 1 (LumA served as the 
reference group), while the IFN and Normal Breast-like groups were not significant. 
Thus, the intrinsic subtypes classifications of LumA, LumB, Basal-like and HER2+/ER- 
add new and important prognostic information beyond what the standard clinical 
predictors provide.   
 
Associations of the Intrinsic subtypes with clinical and biological parameters. To 
further characterize and better understand the intrinsic subtypes, we determined whether 
an association existed between intrinsic subtype and grade, node status, ER status, age, 
and tumor size in the combined test set. Two-way contingency table analysis showed 
significant association between grade and subtype, with HER2+/ER- and Basal-like 
tumors more likely to be grade 3 (Table 2). The Cramer’s V statistic28, which measures 
the strength of association between two variables in a contingency table, indicated a 
substantial association (Cramer’s V>0.36) between grade and subtype. Two-way 
contingency table analysis did not show significant association between node status and 
subtype (p=0.44), but did show significant association between ER status and subtype 
(p<0.0001; Cramer’s V=0.72) and between tumor size and subtype (p=0.01; Cramer’s 
V=0.17). As would be expected, ER+ tumors were more likely to be LumA or LumB. As 
indicated by the low Cramer’s V (Cramer’s V<0.19 indicates a low relationship), tumor 
size and subtype were not strongly correlated.  
To determine association between age and subtype, we used an unpaired 
Student’s t-test to compare the average ages of diagnosis of each tumor subtype. 
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Interestingly, the average age of diagnosis for HER2+/ER- tumors was significantly less 
than that for all other tumor types. The average age of diagnosis for LumA tumors was 
significantly greater than that for LumB tumors. 
 
Derivation and application of a Single Sample Predictor.  A caveat to the above 
analyses is that our classifications were based upon hierarchical clustering, which is a 
powerful tool for intrinsic class discovery, but which is not suited for individual sample 
classification because to classify a new sample would require a reanalysis of all samples. 
Therefore, we wanted to create an unchanging and objective method to classify tumors 
according to intrinsic subtype that could be clinically applicable. To this end, we 
developed a Single Sample Predictor (SSP) using the combined test set hierarchically 
clustered using the 306 Intrinsic/UNC genes (Figure 1). For the SSP, a mean expression 
profile (i.e. centroid) was created for each subtype that was significant in the multivariate 
analysis (LumA, LumB, Basal-like, HER2+/ER-) and for the Normal Breast-like group 
using the combined test set (Figure 2). Next, any new sample is then compared to each 
Centroid and assigned by the SSP to the nearest subtype/centroid as determined by 
Spearman correlation (note: this SSP is based on methods developed by Tibshirani and 
colleagues3,29,30); thus, the SSP contains five different idealized profiles, and any new 
sample is compared to each of the five profiles and assigned a profile label (i.e. subtype 
name) based upon the single idealized profile it most resembled. 
To validate the SSP, we tested it on two additional datasets not used previously. 
The first was the 60-patient Ma et al. dataset, which represents a group of early stage 
ER+ tamoxifen-treated patients6. The SSP classified these samples as follows: 2 Basal-
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like, 2 HER2+/ER-, 12 Normal Breast-like, 34 LumA, and 9 LumB. The 2 Basal-like and 
2 HER2+/ER- assigned samples were excluded from a survival analysis because they 
were too few for a meaningful survival analysis and possibly were misclassified ER-
negative tumors. Among the remaining samples the SSP classification was a significant 
predictor of RFS (p=0.04, Figure 3B), due to the poor outcome of the LumB group. Next, 
we applied the SSP to a 96-sample test set of local only (surgery)-treated patients from 
Chang et al.31. The tumor groups identified by the SSP showed significant differences in 
RFS (Figure 3C, p=0.0006) and OS (p=0.001, data not shown) in Kaplan-Meier analysis, 
with the poor outcome groups as expected: LumB, Basal-like, and HER2+/ER-.  Thus, 
the SSP identified tumor groups that are truly prognostic and have significantly different 
outcomes as was seen before: namely, LumA always has the most favorable outcome, 
while LumB, Basal-like and HER2+/ER- do poorly2,3,9,19. 
We also applied the SSP onto the 105-sample dataset used to derive the 
Intrinsic/UNC gene list, which is technically not a test set for the SSP because it was used 
to derive the Intrinsic/UNC gene set. The tumor groups identified by the SSP showed 
significantly different RFS (Figure 3D, p=0.02) and OS (p=0.03, data not shown) in 
Kaplan-Meier analysis with the poor outcome groups again being LumB, Basal-like, and 
HER2+/ER-.  A subset of the 105-sample dataset (48 in total) had been previously 
characterized using an immunohistochemical (IHC) analysis32, which showed that (1) all 
18 Basal-like tumors were ER-negative and HER2-negative (defined as not having a 3+ 
score on HER2 IHC analysis), (2) all 18 luminal subtype tumors were ER-positive and 
HER2-negative, and (3) all 12 HER2+/ER- subtype tumors were ER-negative and 11 out 
of these 12 showed HER2-overexpression (defined as having a 3+ score on HER2 IHC 
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analysis). Thus, the SSP correlated with many standard clinical parameters, and was also 
able to identify clinically relevant groups (i.e. LumA vs. LumB) not identifiable using the 
standard clinical assays, thus indicating potential value as an objective classification 
method that should be developed further as a clinically applicable test. 
 
DISCUSSION 
The development and validation of gene sets for cancer patients requires 
significant resources because large training and test sets are required to achieve robust 
results. In fact, microarray studies are often criticized for a lack of rigorous validation due 
to small sample sizes17,18. Therefore, we utilized a previously described microarray data 
set combining method (Distance Weighted Discrimination) to create a large validation 
test set of over 300 tumors, and used it to validate a newly derived gene list for breast 
cancer prognostication and prediction. This approach allowed us to perform a 
multivariate analysis in which we show for the first time that the intrinsic subtype 
classification adds valuable information in the presence of five standard clinical 
parameters. We believe this combined test set is a valid test set for use in our analysis 
because after the multiple data sets were combined, the prognostic abilities of the 
standard clinical variables such as ER and grade remained intact.  
The remarkable power of our DWD-based approach is indicated by the fact that 
although samples came from different platforms, hierarchical clustering analysis of the 
combined data set managed to group samples and genes based upon biology, and not 
some artifact caused by combining the data sets together. Evidence that this grouping 
reflected biology and not some artifact comes from (1) the finding that various Gene 
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Ontology terms were significantly over-represented relative to chance in individual gene 
clusters seen in this analysis and (2) the groupings of the samples showed inter-dataset 
mixing and were significant predictors of outcome in univariate Kaplan-Meier and 
multivariate Cox analysis. It is also remarkable that this classification was successful in 
predicting outcome despite the fact that the Intrinsic/UNC gene set was reduced from 
1300 genes to 306 genes in the combined test set; this indicates the robust nature of the 
intrinsic subtypes as defined by the new Intrinsic/UNC gene list. 
One of the accomplishments of this manuscript was to develop an unchanging and 
objective intrinsic subtype predictor that could be used routinely in the clinical setting. 
This was accomplished by first identifying a new intrinsic gene set and then using this set 
to develop the Single Sample Predictor (SSP) that was shown here to be both prognostic 
on the local therapy-only patient subset from Chang et al.31 and predictive of outcomes 
on the ER+ tamoxifen-treated data set of Ma et al.6. Many other gene expression based 
predictors for breast cancer patients have been developed, and in a complementary 
publication33, we tested the intrinsic subtype SSP developed here, relative to those 
predictions made by four other previously published breast cancer prognostic/predictive 
gene sets using a single patient/tumor set of 295 cases; the four other expression-based 
predictors used were (1) the “70-gene” Good vs. Poor outcome predictor developed by 
van’t Veer and colleagues5,11, (2) the “Wound-Response” profile developed by Chang et 
al.31,34, (3) the “Recurrence Score (RS)” profile developed by Paik et al.10, and (4) the 2-
gene (HOXB13:IL17BR) ratio predictor developed by Ma et al.6. The results showed that 
of samples classified as Basal-like, HER2+/ER-, or LumB by the SSP, 93-100% were 
classified by the 70-gene, RS and Wound-Response predictors as being in each 
  63 
  
predictor’s bad prognosis group. These data suggest that a high concordance exists across 
these multiple predictors, in particular the RS, 70-gene and Intrinsic Subtypes; thus, the 
new intrinsic gene list and classification method developed here, when compared to other 
predictors as accomplished in Fan et al.33, showed that a high concordance across 
predictors exists, which provides additional validation for each predictor.  
In summary, the results of this study advances our current knowledge of the 
intrinsic breast tumor subtypes and provides an objective method (SSP) for prospectively 
classifying tumors that could be used in the clinical setting. More broadly speaking, our 
findings show that while the individual brushstrokes (i.e. genes) may sometimes show 
discordance across data sets, the portraits created by the combined patterns of the 
individual brushstrokes is conserved and recognizable across datasets because of the 
similarities to the family portrait24. Moreover, these data show that the breast tumor 
intrinsic subtypes identified using the Intrinsic/UNC gene list can be generalized to many 
different patient sets, both treated and untreated. 
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TABLES 
 
Table 3.1. Multivariate Cox proportional hazards analysis for the 315-sample combined 
test set in relation to Relapse-Free Survival. Multivariate Cox proportional hazards 
analysis of (A) standard clinical factors alone, or with (B) the Intrinsic Subtypes. Size 
was a binary variable (0= diameter of 2cm or less, 1= greater than 2cm); node status was 
a binary variable (0= no positive nodes, 1= one or more positive nodes); age was a 
continuous variable formatted as decade-years. Hazard ratios for Intrinsic Subtypes were 
calculated relative to the Luminal A subtype. Variables found to be significant (p<0.05) 
in the Cox proportional hazards model are shown in bold.  
A.      Relapse-Free survival  
Variable 
 
Hazard Ratio 
(95% CI) 
p-value 
 
Age, per decade 
 
ER status 
 
Node status 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
 
1.04 (0.90-1.20) 
 
0.59 (0.41-0.83) 
 
1.41 (0.98-2.04) 
 
2.41 (1.08-5.36) 
 
3.98 (1.80-8.82) 
 
1.60 (1.31-1.95) 
 
0.64 
 
0.003 
 
0.07 
 
0.032 
 
0.0007 
 
<0.0001 
B.      Relapse-Free survival  
Variable 
 
Hazard Ratio 
(95% CI) 
p-value 
 
Age, per decade 
 
ER status 
 
Node status 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
Basal-like vs. LumA 
 
HER2+/ER- vs. LumA 
 
LumB vs. LumA 
 
IFN vs. LumA 
 
Normal-like vs. LumA 
 
1.08 (0.94-1.24) 
 
0.69 (0.42-1.13) 
 
1.35 (0.92-1.98) 
 
1.88 (0.82-4.32) 
 
2.58 (1.08-6.12) 
 
1.59 (1.30-1.95) 
 
2.02 (1.05-3.90) 
 
3.47 (1.78-6.76) 
 
1.92 (1.07-3.45) 
 
1.40 (0.67-2.91) 
 
1.56 (0.59-4.16) 
 
 
0.29 
 
0.14 
 
0.13 
 
0.14 
 
0.03 
 
<0.0001 
 
0.036 
 
0.0003 
 
0.028 
 
0.37 
 
0.37 
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Table 3.2. Association between tumor histologic grade and intrinsic subtype in the 315-
sample combined test set. 
 
         Intrinsic Subtype 
Two-way 
contingency table 
 
 
LumA 
 
 
(# of pts.) 
LumB 
 
 
(# of pts.) 
IFN 
 
 
(# of pts.) 
HER2+/ER- 
 
 
(# of pts.) 
Basal-like 
 
 
(# of pts.) 
Grade 
 
1 (well) 
 
 
29 
 
 
2 
 
 
1 
 
 
0 
 
 
1 
 
2 (intermediate) 
 
45 
 
26 
 
8 
 
6 
 
16 
 
3 (poor) 
 
15 
 
32 
 
16 
 
21 
 
67 
 
Statistics for two-way contingency table analysis 
 
p-value†                <0.0001 
 
Cramer’s V††         0.42 
 
† p-value calculated from Chi-square test on contingency table. †† Cramer’s V statistic 
(value can range from 0 to 1) measures the strength of association between the two 
variables analyzed in the contingency table, with 1 indicating perfect association and 0 
indicating no association.  
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FIGURES 
 
 
 
 
Figure 3.1. Overview of the analysis methods and datasets used.
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Figure 3.2. Hierarchical cluster analysis of the 315-sample combined test set using the 
Intrinsic/UNC gene set reduced to 306 genes. (A) Overview of complete cluster diagram. 
(B) Experimental sample-associated dendrogram. (C) Luminal/ER+ gene cluster with 
GATA3-regulated genes highlighted in pink. (D) HER2 and GRB7-containing expression 
cluster. (E) Interferon-regulated cluster containing STAT1. (F) Basal epithelial cluster. 
(G) Proliferation cluster. 
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Figure 3.3. Kaplan-Meier survival curves of breast tumors classified by intrinsic subtype. 
Survival curves are shown for (A) the 315-sample combined test set classified by 
hierarchical clustering using the Intrinsic/UNC gene set and (B) the 60-sample Ma et al., 
(C) 96-sample Chang et al., and (D) 105-sample (used to derive the Intrinsic/UNC gene 
set) datasets classified by the Nearest-Centroid predictor (Single Sample Predictor). 
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Figure 3.4. Kaplan-Meier survival curves using RFS as the endpoint, for the common 
clinical parameters present within the 315-sample combined test set. Survival curves are 
shown for (A) ER status, (B) node status, (C) histologic grade (1=well-differentiated, 
2=intermediate, 3=poor), and (D) tumor size (1= diameter of 2cm or less; 2=diameter 
greater than 2cm and less than or equal to 5cm; 3=diameter greater than 5cm; 4=any size 
with direct extension to chest wall or skin). 
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ABSTRACT 
Background. Gene expression profiling studies of primary breast tumors performed by 
different laboratories have resulted in the identification of many apparently different 
prognostic profiles/gene sets, which show little overlap in gene identity.  
Methods. In order to compare the individual sample predictions made by these different 
gene sets, we applied to a single dataset of 295 samples, five different gene expression-
based predictors: (1) Intrinsic Subtypes1, 2, (2) 70-gene Good vs. Poor3, 4, (3) Wound-
Response Activated vs. Quiescent5, 6, (4) Recurrence Score7, and (5) the 2-gene ratio 
profile for tamoxifen-treated patients8.  
Results. There was high concordance in outcome predictions across most of these 
different predictors when the outcome predictions on individual samples were compared. 
In particular, patients of the Basal-like, HER2+/ER- and Luminal B Intrinsic Subtypes 
were almost all 70-gene Poor, Wound-Response Activated, and had a High Recurrence 
Score. The 70-gene and Recurrence Score predictors, which are beginning to be used in 
the clinical setting, showed 77-81% agreement.  
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Conclusions. These data show that even though different gene sets are being used for 
prognostication on breast cancer patients, four of the profiles tested here showed 
significant agreement in outcome predictions on individual patients and are likely 
tracking a common set of biological phenotypes. 
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INTRODUCTION 
Many different gene expression studies have identified expression profiles/gene 
sets that are prognostic and/or predictive for breast cancer patients2-12. Comparison of the 
gene lists derived from some of these apparently similar studies show that they overlap 
with each other by a modest amount, if at all. The reasons for this lower-than-expected 
overlap are not completely known but must include differences in patient cohorts, 
microarray platforms and mathematical analysis methods. An important and unanswered 
question, however, is whether these predictors actually disagree or agree concerning 
outcome predictions for the individual patient. Here we describe an analysis of a single 
dataset on which five different prognostic/predictive gene expression-based predictors 
were simultaneously compared. This “across profile” analysis showed that different 
predictors had significant concordance when outcome predictions on individual patients 
were compared, despite the fact that these predictors had little gene overlap. 
 
MATERIALS AND METHODS 
Patient data set. For this study, we used a single dataset of 295 samples produced by 
researchers from the Netherlands Cancer Institute (NKI) using Agilent Oligo 
microarrays, and for which Relapse-Free Survival (RFS, scored as time to first event) and 
Overall Survival (OS) data were available3-5. The clinical information associated with 
these patients was obtained from the supporting website for the Chang et al. 2005 paper; 
this patient set contained predominantly Stage I and II patients who received either local 
therapy only (n=165), tamoxifen only (n=20), tamoxifen plus chemotherapy (n=20) or 
chemotherapy only (n=90).  
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Statistical methods. Five different prognostic/predictive gene sets (and methodologies) 
were tested on this single dataset and the results were recorded for each predictor on each 
patient (see Table 1 for a summary of the classifications made by the five predictors). The 
expression-based predictors used were (1) the “70-gene” Good vs. Poor outcome 
predictor developed by van’t Veer, van de Vijver and colleagues3, 4, (2) the “Wound-
Response” profile developed by Chang et al.5, 6, (3) the “Recurrence Score (RS)” profile 
developed by Paik, Shak et al.7, (4) the “Intrinsic Subtype” classifications developed by 
Perou, Sorlie and colleagues1, 2, 10, 13, and (5) the 2-gene (HOXB13:IL17BR) ratio 
predictor8. The RS and 2-gene ratio predictors were originally designed for outcome 
predictions on Estrogen Receptor (ER)-positive tamoxifen-treated patients7, 8, and we 
therefore performed analysis for the ER+ patient subset on its own, in addition to the 
complete set of ER+ and ER– samples combined. Many other prognostic profiles exist 
for breast cancer patients. We excluded some of these for a lack of sufficient numbers of 
genes, the expression of which was captured in the NKI data set, or because the 
description of the predictor was too vague to be confidently applied to a new data set. 
Additionally, it is beyond the scope of this work to test every possible published breast 
cancer predictor. 
For the 70-gene and Wound-Response predictions, we used the individual sample 
assignments provided by Chang et al.5. Briefly, the assignments made by the 70-gene and 
Wound-Response predictors were as follows: for the 70-gene predictor, a sample was 
classified according to the correlation of its expression levels of the 70 genes to a 
previously determined average centroid/profile of these genes in tumors from patients 
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with the “Good” prognosis profile. Patients with a correlation coefficient of >0.4 were 
classified as Good, and  ≤0.4 as Poor3, 4. For the Wound-Response predictor, a sample 
was classified according to the Pearson correlation of its expression levels of the “core 
serum response (CSR)” genes to the serum-activated fibroblast centroid. Patients with >-
0.15 correlation were classified as Wound-Response Activated, and  ≤-0.15 as Wound-
Response Quiescent5.  
We used a nearest centroid predictor1 to classify tumors according to “Intrinsic 
Subtype”.  Briefly, a new “intrinsic” gene set was developed as described in Sorlie et al. 
20032, using 24 new paired tumor samples assayed on Agilent Oligo microarrays, and 
105 tumors in total. Next, this gene list was used in a hierarchical clustering analysis on a 
311 tumor sample test set created by combining together the two-color DNA microarray 
data sets of Sorlie et al. 2001 and 20032, 10, van’t Veer et al.4 and Sotiriou et al.11. This 
cluster was then used as the starting point to create five Subtype Mean expression 
profiles/Centroids (Luminal A, Luminal B, HER2+/ER-, Basal-like and Normal-like) by 
averaging the gene expression profiles for the samples within each dendrogram 
branch/subtype. Finally, new samples like those in the Chang et al. dataset, are then 
individually compared to each centroid using the 306 intrinsic genes, and are assigned to 
the nearest centroid as determined by Spearman correlation. For more details on this 
nearest centroid predictor (also referred to as a Single Sample Predictor), the data and 
how to implement it, see https://genome.unc.edu/pubsup/breastTumor/.  
To classify tumors using the Recurrence Score predictor, we used the microarray 
data for all 21 RS-genes and applied the algorithm and scaling methods described in Paik 
et al. (2004). Briefly, the expression of the 16 target genes was normalized relative to the 
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5 reference genes; next, the target genes were scaled as described for the qRT-PCR data, 
weighted averaging was performed and we then used these values and the RS algorithm 
to generate a Recurrence Score for each patient, which ranged from 0 to 100; scaling was 
done separately for the 295 patient group and for the 225 ER+ patient group. Using the 
cutoffs described in Paik et al. (0-18, 19-30, 31-100), we assigned each patient into the 
Low, Intermediate or High risk groups. Finally, we used the log-base-2 ratio of 
HOXB13:IL17BR as a means of patient stratification, using a cutoff of -0.15 as described 
in Ma et al.8 to classify patients as having either a High or Low 2-gene ratio.  
It should be noted that for the 70-gene, Wound-Response and Intrinsic Subtype 
profiles, a subset of the samples in this 295-sample dataset were used to train these 
predictors (75 of the 295 samples were previously published4 and used to train the 70-
gene profile, these same 75 samples were also part of the 311 tumor dataset used to 
derive the Intrinsic Subtype Centroid profiles1, and 148 of the 295 samples were 
randomly selected to train the Wound-Response profile5). Therefore, their performance in 
the Kaplan-Meier and multivariate analyses described below is positively biased. 
However, as this paper is focused on comparing the actual predictions themselves and is 
not focused on identifying the “best” predictor, we believed it best to include as many 
samples as possible in the analysis as opposed to removing subsets of samples due to 
training and test set issues (if we removed training set samples, the resulting test dataset 
would be greatly reduced — to fewer than 147 samples and possibly as few as 72 
samples). We acknowledge that the RS and 2-gene predictors are thus at a prognostic 
disadvantage relative to the other three because the 295 samples represent a true test set 
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for these two predictors; this point should be taken into consideration when interpreting 
the results of the survival analyses and hazard ratios from multivariate analyses. 
 
Survival Analyses. To evaluate the prognostic value of each gene expression-based 
predictor, we performed univariate Kaplan-Meier analysis using the Cox-Mantel log-rank 
test in WinSTAT for Excel (R. Fitch Software, Staufen, Germany). We also performed a 
multivariate Cox proportional hazards analysis (SAS, Cary, NC) of each predictor 
individually in a model that included ER status (positive vs. negative), grade (1 vs. 2, and 
1 vs. 3), node status (0 vs. 1-3 positive nodes, and 0 vs. >3 positive nodes), age (as a 
continuous variable), tumor size (≤2cm vs. >2cm), and treatment status (no adjuvant 
therapy vs. chemotherapy and/or hormonal therapy), with Relapse Free Survival (RFS, 
defined as time to first event) and Overall Survival (OS) as the endpoints (note: for 
multivariate analysis of the Intrinsic Subtypes and RS, ER status was not included as a 
variable because it was based upon the same microarray data that was used as part of 
these gene expression predictors). Two-way contingency table analyses and calculation 
of Cramer’s V statistic were performed using WinSTAT for Excel. The Cramer’s V 
statistic provides a quantitative measure of the strength of association between the two 
variables in a contingency table (which cannot be obtained from the p-value): Cramer’s V 
values range from 0 to 1, with 0 indicating no relationship and 1 indicating perfect 
association. Traditionally, values between 0.36 and 0.49 indicate a substantial 
relationship and values >0.50 indicate a very strong relationship. The V statistic is a 
generalization of the more familiar phi statistic to non 2x2 contingency tables, and for 
2x2 tables the V statistic is equal to the phi statistic14.  
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RESULTS 
Analysis of all 295 tumors. Each of the five predictors (except for the 2-gene ratio 
predictor), ER status, grade, tumor size (≤2cm  vs. >2cm) and node status (0 vs. 1-3 vs. 
>3 nodes) were statistically significant predictors of Relapse-Free (RFS) and Overall 
Survival (OS) using univariate Kaplan-Meier survival analyses (Figure 1 and Table 1 
shows a summary of how the five predictors classified the 295 samples). For the 2-gene 
ratio predictor, tumors with a High gene ratio were expected to be the poor outcome 
group (Figure 2 of Ma et al., 2004), but this was not observed in the 295-tumor dataset 
(Figure 1I, J). For the other four predictors, the poor outcome groups observed in the 295-
tumor dataset were as expected: (1) 70-gene Poor, (2) Wound-Response Activated, (3) 
High Recurrence Score, and (4) Basal-like, Luminal B, and HER2+/ER- Intrinsic 
Subtypes. To evaluate the prognostic value of each gene expression-based predictor, we 
next performed multivariate Cox proportional hazards analysis of each predictor 
individually in a model that included ER status, grade, node status, age, tumor size, and 
treatment status (Table 2). The Intrinsic Subtypes, 70-gene, Wound-Response and RS 
classification schemes were significant predictors in these models for both RFS and OS, 
showing that individually, each gene expression profile (except for the 2-gene predictor) 
adds new and important prognostic information beyond what the standard clinical 
predictors provide. In fact, the 70-gene, RS and Intrinsic Subtypes were the most 
predictive variables in each model as determined by the lowest nominal p-value. 
As a point of reference, we next analyzed each predictor relative to the Intrinsic 
Subtype assignments, which is an assignment that is largely based upon an 
“unsupervised” analysis of breast tumor gene expression profiles (Table 3). For the 53 
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Basal-like tumors, all were classified as RS High, 70-gene Poor, and 50/53 were Wound-
Response Activated. A nearly identical finding was also observed for the second ER-
negative subtype (HER2+/ER-), and for the poor outcome, clinically ER+, Luminal B 
tumor group. Conversely, the Normal-like and Luminal A subtype tumors showed 
significant heterogeneity in terms of how samples were classified by the other predictors; 
however, 62/70 RS Low samples were in the Luminal A subtype. These data suggest that 
if a sample is classified as Basal-like, HER2+/ER-, or Luminal B, then one should be 
able to infer with high accuracy, that it would be classed in the bad prognosis groups of 
the 70-gene, Wound-Response and RS predictors.  
We next compared the 70-gene, Wound-Response, RS and 2-gene predictor 
assignments to each other using two-way contingency table analyses (note: for these 
analyses, we combined the RS categories Low and Intermediate into a single group 
because they showed survival curves that were not significantly different [see Table 2E]). 
All comparisons yielded statistically significant correlations, with the least correlated 
profile being the 2-gene predictor. The RS, 70-gene and Wound-Response profiles were 
all highly correlated with each other (Table 4, Chi-square p-values <0.001). We then 
assessed the strength of correlation between the predictors using the Cramer’s V statistic. 
Comparing the 70-gene vs. RS gave a Cramer’s V=0.60 (indicates a strong relationship), 
RS vs. Wound-Response V=0.42 (substantial relationship), and the 70-gene vs. Wound-
Response V=0.36 (substantial relationship). Thus, most tumors classified as having poor 
outcome by one of these three predictors were also classified as such by the other two. By 
comparing these Cramer’s V values, the predictor showing the best agreement with the 
other two was the Recurrence Score (i.e. out of the three, the Recurrence Score was the 
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closest to functioning as a consensus predictor). To determine if combining the three 
predictors could result in a better predictor, we derived a predictor based on the majority 
vote of the three predictors. This predictor’s performance in Kaplan-Meier analysis was 
comparable to that of the three predictors individually, but was not noticeably better.  
Grade is an important clinical and biological feature of tumors, especially when 
one compares the clinical behavior of grade 1 vs. grade 3 breast tumors. Correlation with 
grade is an often-asked question regarding these new gene-expression based predictors. 
We therefore performed two-way contingency table analysis comparing each predictor to 
grade. Of the four predictors tested (70-gene, Wound-Response, 2-gene ratio, and RS as 2 
classes [Low + Intermediate vs. High]), all showed significant correlation with grade 
(p<0.001). The profile with the strongest correlation with grade was the 70-gene, which 
gave a Cramer’s V=0.52, next was RS (V=0.48), then Wound Response (V=0.35) and 
finally the 2-gene ratio (V=0.25). Thus, to varying degrees, all the predictors correlated 
with grade, however, it should be noted that because the 70-gene, RS, Intrinsic Subtypes 
and Wound-Response profiles were all significant predictors in the multivariate analyses 
that included grade, these predictors add prognostic information beyond that provided by 
grade. Moreover each of these predictors offers an assay that could be easily standardized 
across institutions and would be objective, quantitative, and automatable. 
The 70-gene3, 4 and RS7, 15 predictors are the most advanced in terms of validation 
and are beginning to be used in the clinical setting to assist in making treatment 
decisions. We therefore specifically compared these two predictors to one another. A 
simple way to compare their predictions is to call a RS “Low” and “Intermediate” 
equivalent to a 70-gene “Good”, a RS “High” equivalent to a 70-gene “Poor”, and 
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determine how many samples agreed. Using this criteria, there was agreement in 239/298 
(81%) of the cases. In particular, 81/103 RS “Low” and “Intermediate” patients were 
classified as 70-gene “Good”. It should be noted that here we compared the predictors for 
their capacity to predict recurrence of disease in a group of patients that were both lymph 
node negative and positive. These two predictors, however, were developed to predict 
distant metastasis-free survival in lymph node-negative patients only and are either meant 
to be used to predict prognosis without adjuvant treatment (70-gene predictor) or for 
tamoxifen-treated patients (RS).   
 
Analysis of ER+ tumors. Two of the five predictors (RS and 2-gene ratio) were 
specifically designed for ER+ patients only. We therefore performed similar analyses as 
described above (Table 1) on only those 225 patients in this dataset who were classified 
as ER+ (which was based on a gene expression-based cutoff using the mRNA for ER, see 
Chang et al.5). Again, all the gene expression-based predictors, except for the 2-gene 
ratio predictor, were significant predictors of RFS and OS in univariate Kaplan-Meier 
analysis (Figure 2). In multivariate Cox proportional hazards analyses in which each 
predictor was evaluated individually in a model that included the standard clinical 
variables, the 70-gene, Wound-Response, Intrinsic Subtypes Luminal A vs. B, and RS 
added significant prognostic information regarding RFS and OS; again, each gene 
expression predictor typically gave the lowest p-value when compared with the 
traditional clinical variables (Table 5). Interestingly, when samples within the ER+ 
patient subset were classified according to Intrinsic Subtype (Table 6), 7 were Basal-like 
and 18 were HER2+/ER-, suggesting that approximately 10% of ER+ samples fell into 
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tumor subtype categories that we consider to be “ER-negative” as determined by 
hierarchical clustering analysis. 
As was done for the 295-sample set, we did a pair-wise comparison of the 70-
gene, Wound-Response, RS and 2-gene predictor assignments for the 225 ER+ patients 
using two-way contingency table analyses. All comparisons yielded statistically 
significant correlations except for the 2-gene predictor (Table 7). The RS, 70-gene and 
Wound-Response profiles were highly correlated with each other (p<0.001); the observed 
Cramer’s V values were 0.54 for 70-gene vs. RS (very strong relationship), 0.38 for RS 
vs. Wound-Response (substantial relationship), and 0.34 for 70-gene vs. Wound-
Response (moderate relationship). From the Cramer’s V values, we again see that the 
predictor showing the best agreement with the other two predictors was the Recurrence 
Score. We again derived a predictor based on the majority vote of the three predictors and 
as was seen before, its performance in Kaplan-Meier analysis was comparable to the 
three individual predictors, but was not noticeably better.  
When RS “Low” and “Intermediate” vs. “High” classification was compared to 
the 70-gene “Good” vs. “Poor”, 173/225 samples (77%) showed agreement. In particular, 
of the 105 RS “Low” or “Intermediate” patients, 83 were classified as 70-gene “Good”. 
Finally, we did not perform any multivariate Cox proportional hazards analyses using all 
predictors simultaneously to identify the “optimal model” because we believe that this 
would not be a fair test for either of those predictors (RS and 2-gene ratio) for which this 
was a true test set, or for those that were derived using a different platform (RS, 2-gene 
and Intrinsic Subtypes). 
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DISCUSSION 
A plethora of gene expression-based prognosticators are being developed for 
outcome predictions in breast cancer patients. In this study, we took advantage of a single 
dataset that had enough genes assayed to allow the simultaneous analysis of five different 
gene expression-based predictors and determined that most of these assays were making 
similar predictions; that is, if one predictor assigned a sample to its “poor outcome” 
group, then another predictor also assigned that same sample to its “poor outcome” 
group. In the case of tumors of the Intrinsic Subtype classes Basal-like, HER2+/ER- and 
Luminal B, the assignments made by the 70-gene, RS and Wound-Response predictors 
were almost homogeneously into the relevant poor outcome groups (regardless of ER 
status). It is only within the Luminal A and Normal-like Intrinsic Subtypes where 
variability in outcome predictions was found. Of the five predictors analyzed in this 
report, only the 2-gene predictor failed to identify statistically significant outcome 
differences on this dataset; Reid et al. also reported that on their independent dataset of 
ER+ tamoxifen-treated patients, the 2-gene predictor failed to detect outcome 
differences16.  
When the 70-gene, Wound-Response, RS and 2-gene predictors were compared in 
a pair-wise fashion, it was determined that the 70-gene, Wound-Response and RS 
classifications were highly concordant. When the 70-gene and RS predictors were 
compared relative to each other, they agreed on sample predictions for 77% (ER+) and 
81% (ER+ and ER-) of the patients. These analyses suggest that even though there is very 
little gene overlap (the 70-gene and RS overlap by only one gene: SCUBE2), and 
different algorithms are used, the majority of breast cancer patients would receive similar 
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outcome predictions when these different methods and models are used. It is also likely 
that the RS predictor, originally developed for only ER+ patients, “worked” on all 
patients because we can see that almost all (69/70) ER-negative patients were classified 
as being in the poor outcome RS High group (and they in fact do show poor outcomes). 
The outcome predictions by the different methods (with the exception of the 2-gene 
predictor) largely overlap when evaluated by the multivariate Cox proportional hazards 
analyses (95% Confidence Intervals of Hazard Ratios in Table 2). The proportion of 
patients identified as “poor outcome” or “good outcome” as outlined above is also highly 
similar. The discordance of up to 20% of the patients in different categories leads to 
slight differences in outcome prediction and underlines the need of further validations. In 
the coming years a NCI (PACCT), as well as an European Union (TRANSBIG-
MINDACT) randomized clinical trial will prospectively address the power of the RS and 
70-gene test respectively. 
We believe that despite the lack of gene overlap, the different gene sets/profiles 
are making similar predictions largely because they are tracking common cellular 
phenotypes that are reflective of the dominant biology of breast tumors, which 
encompasses the consistent differences seen in ER-positive (i.e. Luminal) vs. ER-
negative breast cancers (Basal-like and HER2+/ER-). While these distinctions are 
correlated with grade, which is another common biological phenotype that these gene 
profiles are tracking, it is also clear that these profiles are providing additional 
information beyond that provided by grade, as evidenced by their significance in Cox 
regression analyses. These findings also show that prognostic profiles can be readily 
detected by a great number of genes, and any sufficiently representative subset of these 
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genes could potentially be used as a predictor. This phenomenon has been observed in 
normal tissues: Son et al. reported that approximately 19,000 genes are differentially 
expressed between different organs, and any sufficiently large (approximately 100) 
randomly selected subset could reproduce the hierarchical clustering pattern produced 
when using the full gene set17. An important implication of these findings is that when 
comparing two “profiles”, overlap in gene identity is not a good measure of 
reproducibility and that individual sample classifications is the relevant measure of 
concordance. 
We find these results encouraging and interpret them to mean that although 
different gene sets are being used, they are each tracking a common set of biological 
characteristics that are present across different breast cancer patient sets and are making 
similar outcome predictions. The next question to ask is what outcome predictor(s) should 
be used and why. The answer cannot be determined based upon the analyses in this 
report, but the guiding principle should be to use the predictor(s) that will predict patient 
outcomes and assist in making therapeutic decisions (i.e. predictive assays) within a 
specified group. For example, if a patient is determined to be of the Intrinsic Subtypes of 
Basal-like, HER2+/ER- or Luminal B, or “poor outcome” by the RS or 70-gene test, then 
there is, as yet, little need to perform the other assays because they would all indicate a 
poor prognosis. Thus, future studies should focus on developing assays that can 
prognosticate within HER2+/ER-, Basal-like, and Luminal B patients. For patients of the 
Luminal A and Normal-like Intrinsic Subtypes, the RS, 70-gene and Wound-Response 
profiles provided additional information (Tables 3 and 6) that may be useful in guiding 
treatment decision. For example, Luminal A patients with a Low RS might be selected to 
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receive only hormone therapy because a Low RS is associated with good outcomes in 
tamoxifen-treated patients and little benefit from chemotherapy7, 15. Retrospective and 
prospective studies must now be done to determine which is the “best” predictor, but it is 
likely that the “best” predictor may be a combination of two or more different predictors.  
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TABLES 
 
Table 4.1. Summary of the classifications of the NKI patient dataset using five different 
gene expression-based profiles. 
 
Dataset 
 
Classification Method 
295-sample dataset 
 
number of patients (%) 
ER+ 225-sample dataset 
number of patients (%) 
Intrinsic Subtype 
Luminal A 
Luminal B 
Normal-like 
HER2+/ER- 
Basal-like 
 
 
123 (41.7%) 
55 (18.6%) 
29 (9.8%) 
35 (11.9%) 
53 (18.0%) 
 
 
121 (53.8%) 
55 (24.4%) 
24 (10.7%) 
18 (8.0%) 
7 (3.1%) 
Recurrence Score 
Low 
Intermediate 
High 
 
 
70 (23.7%) 
33 (11.2%) 
192 (65.1%) 
 
 
87 (38.7%) 
18 (8.0%) 
120 (53.3%) 
70-gene 
 
Good 
Poor 
 
 
115 (39.0%) 
180 (61.0%) 
 
 
113 (50.2%) 
112 (49.8%) 
Wound Response 
Quiescent 
Activated 
 
 
67 (29.8%) 
228 (77.3%) 
 
 
60 (26.7%) 
165 (73.3%) 
2-gene ratio 
Low 
High 
 
 
137 (46.4%) 
158 (53.6%) 
 
 
122 (54.2%) 
103 (45.8%) 
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Table 4.2. Multivariate Cox proportional hazards analysis for the 295-sample Chang et 
al. 2005 dataset in relation to Relapse-Free Survival and Overall Survival. Multivariate 
Cox proportional hazards analysis of (A) standard clinical prognostic factors alone, or 
with (B) the 70-gene predictor, (C) Wound-response predictor, (D) Ma et al. 2-gene ratio 
predictor, (E) Recurrence Score, or (F) Intrinsic Subtypes in relation to Relapse-Free 
Survival and Overall Survival. Size was a binary variable (0= diameter of 2cm or less, 1= 
greater than 2cm); age was a continuous variable formatted as decade-years; hazard ratios 
for Intrinsic Subtypes were calculated relative to the Luminal A subtype. Variables found 
to be significant (p<0.05) in the Cox proportional hazards model are shown in bold. 
 
 
A.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
ER status 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
0.59 (0.43-0.82) 
 
0.65 (0.42-0.99) 
 
2.45 (1.33-4.50) 
 
2.53 (1.35-4.74) 
 
1.40 (0.96-2.05) 
 
1.32 (0.72-2.41) 
 
2.24 (1.12-4.49) 
 
0.56 (0.31-1.01) 
 
0.001 
 
0.045 
 
0.004 
 
0.004 
 
0.083 
 
0.37 
 
0.023 
 
0.055 
 
0.67 (0.45-0.98) 
 
0.44 (0.27-0.71) 
 
4.31 (1.49-12.47) 
 
5.96 (2.06-17.21) 
 
1.52 (0.94-2.43) 
 
1.06 (0.48-2.36) 
 
1.85 (0.78-4.38) 
 
0.81 (0.38-1.74) 
 
 
0.042 
 
0.001 
 
0.007 
 
0.001 
 
0.086 
 
0.88 
 
0.16 
 
0.59 
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B.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
ER status 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
70-gene predictor  
(poor vs. good) 
 
0.64 (0.46-0.88) 
 
0.86 (0.56-1.31) 
 
1.57 (0.82-2.97) 
 
1.32 (0.68-2.59) 
 
1.44 (0.99-2.11) 
 
1.20 (0.66-2.18) 
 
2.19 (1.07-4.47) 
 
0.54 (0.30-0.99) 
 
 
3.44 (1.98-5.99) 
 
 
0.006 
 
0.47 
 
0.17 
 
0.41 
 
0.059 
 
0.55 
 
0.032 
 
0.048 
 
 
<0.001 
 
0.71 (0.48-1.05) 
 
0.59 (0.36-0.95) 
 
2.55 (0.86-7.63) 
 
2.84 (0.94-8.54) 
 
1.58 (0.98-2.53) 
 
1.01 (0.46-2.21) 
 
1.97 (0.81-4.79) 
 
0.75 (0.34-1.62) 
 
 
4.71 (2.02-11.00) 
 
 
0.085 
 
0.031 
 
0.093 
 
0.064 
 
0.058 
 
0.97 
 
0.14 
 
0.46 
 
 
<0.001 
 
 
C.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
 
Age, per decade 
 
ER status 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
Wound-response signature 
(activated vs. quiescent) 
 
 
0.56 (0.40-0.77) 
 
0.69 (0.45-1.06) 
 
1.89 (1.02-3.52) 
 
1.92 (1.02-3.62) 
 
1.39 (0.95-2.03) 
 
1.19 (0.65-2.17) 
 
1.74 (0.85-3.57) 
 
0.58 (0.32-1.07) 
 
 
2.88 (1.50-5.52) 
 
 
 
<0.001 
 
0.089 
 
0.045 
 
0.045 
 
0.090 
 
0.58 
 
0.13 
 
0.080 
 
 
0.002 
 
 
0.62 (0.41-0.92) 
 
0.46 (0.28-0.76) 
 
3.32 (1.13-9.71) 
 
4.46 (1.53-13.00) 
 
1.52 (0.95-2.44) 
 
0.96 (0.43-2.12) 
 
1.48 (0.61-3.59) 
 
0.84 (0.39-1.81) 
 
 
3.25 (1.27-8.27) 
 
 
 
0.019 
 
0.002 
 
0.028 
 
0.006 
 
0.083 
 
0.92 
 
0.38 
 
0.65 
 
 
0.014 
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D.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
ER status 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
Ma et al. 2-gene ratio 
(high vs. low) 
 
0.60 (0.43-0.82) 
 
0.63 (0.41-0.98) 
 
2.43 (1.32-4.47) 
 
2.57 (1.37-4.82) 
 
1.40 (0.96-2.05) 
 
1.32 (0.72-2.42) 
 
2.26 (1.13-4.54) 
 
0.55 (0.30-1.00) 
 
 
0.91 (0.61-1.34) 
 
0.001 
 
0.040 
 
0.004 
 
0.003 
 
0.082 
 
0.36 
 
0.022 
 
0.051 
 
 
0.62 
 
0.67 (0.45-0.98) 
 
0.44 (0.26-0.72) 
 
4.31 (1.49-12.48) 
 
5.96 (2.06-17.23) 
 
1.52 (0.94-2.43) 
 
1.06 (0.48-2.36) 
 
1.85 (0.78-4.38) 
 
0.81 (0.38-1.74) 
 
 
1.00 (0.61-1.63) 
 
0.042 
 
0.001 
 
0.007 
 
0.001 
 
0.086 
 
0.88 
 
0.16 
 
0.59 
 
 
0.99 
 
 
E.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
Intermediate vs. Low 
recurrence score 
 
High vs. Low  
recurrence score 
 
0.57 (0.42-0.79) 
 
1.61 (0.85-3.04) 
 
1.50 (0.79-2.86) 
 
1.51 (1.03-2.20) 
 
1.24 (0.68-2.26) 
 
2.10 (1.04-4.25) 
 
0.54 (0.30-0.98) 
 
 
1.81 (0.70-4.68) 
 
 
4.27 (2.05-8.92) 
 
<0.001 
 
0.14 
 
0.21 
 
0.035 
 
0.48 
 
0.039 
 
0.044 
 
 
0.22 
 
 
<0.001 
 
0.63 (0.42-0.94) 
 
2.95 (0.99-8.73) 
 
3.81 (1.30-11.1) 
 
1.66 (1.03-2.67) 
 
0.95 (0.43-2.09) 
 
1.59 (0.66-3.82) 
 
0.80 (0.37-1.73) 
 
 
1.81 (0.39-8.27) 
 
 
6.14 (1.84-20.4) 
 
 
0.023 
 
0.051 
 
0.014 
 
0.036 
 
0.90 
 
0.30 
 
0.57 
 
 
0.45 
 
 
0.003 
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F.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy  
 
Luminal B 
 
Normal-like 
 
Her2+/ER- 
 
Basal-like 
 
0.59 (0.42-0.82) 
 
1.80 (0.96-3.39) 
 
1.80 (0.92-3.50) 
 
1.55 (1.05-2.29) 
 
1.20 (0.65-2.21) 
 
2.01 (0.96-4.21) 
 
0.49 (0.26-0.92) 
 
 
3.79 (2.17-6.61) 
 
2.86 (1.49-5.50) 
 
3.16 (1.61-6.18) 
 
2.45 (1.33-4.51) 
 
0.002 
 
0.068 
 
0.087 
 
0.027 
 
0.55 
 
0.064 
 
0.025 
 
 
<0.001 
 
0.002 
 
<0.001 
 
0.004 
 
0.67 (0.45-1.00) 
 
3.51 (1.19-10.36) 
 
4.47 (1.48-13.49) 
 
1.55 (0.96-2.51) 
 
1.01 (0.45-2.28) 
 
1.81 (0.73-4.50) 
 
0.69 (0.31-1.54) 
 
 
2.55 (1.25-5.22) 
 
2.00 (0.76-5.31) 
 
3.54 (1.59-7.85) 
 
3.05 (1.49-6.27) 
 
0.051 
 
0.023 
 
0.008 
 
0.076 
 
0.98 
 
0.20 
 
0.37 
 
 
0.010 
 
0.16 
 
0.002 
 
0.002 
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Table 4.3. Comparison of predictors for all 295 samples. 
Intrinsic 
Subtype # Recurrence Score 70-gene Wound-Response 2-gene 
Low 0 good 0 Quiescent 3 Low 11 
Intermediate 0             
Basal-like 53 high 53 poor 53 Activated 50 high 42 
Low 62 good 87 Quiescent 45 Low 78 
Intermediate 25             
Luminal A 123 high 36 poor 36 Activated 78 high 45 
Low 1 good 9 Quiescent 4 Low 30 
Intermediate 4             
Luminal B 55 high 50 poor 46 Activated 51 high 25 
Low 0 good 3 Quiescent 0 Low 7 
Intermediate 0             
HER2+/ER- 35 high 35 poor 32 Activated 35 high 28 
Low 7 good 16 Quiescent 15 Low 11 
Intermediate 4             
Normal-like 29 high 18 poor 13 Activated 14 high 18 
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Table 4.4. Two-way contingency table analysis measuring the association between the 
70-gene, Wound-response, and Recurrence Score predictors in the 295-sample dataset.  
 
A.  
 
  Wound-Response  
 
  Quiescent        Activated 
             (# of patients) 
Two-way contingency table 
 
 
 
 
70-gene predictor  
               Good 
                Poor 
 
48 
19 
 
67 
161 
Statistics for two-way 
contingency table analysis  
 
p-value† 
 
Cramer’s V†† 
 
 
 
 
<0.001 
 
0.36 
 
 
B.  
 
  Recurrence Score  
 
  Low or Int.        High 
          (# of patients) 
Two-way contingency table 
 
 
 
 
70-gene predictor  
               Good 
                Poor 
 
81 
22 
 
34 
158 
Statistics for two-way 
contingency table analysis  
 
p-value† 
 
Cramer’s V†† 
 
 
 
 
<0.001 
 
0.60 
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C. 
 
  Recurrence Score  
 
  Low or Int.        High 
          (# of patients) 
Two-way contingency table 
 
 
 
 
Wound Response  
                Quiescent 
                Activated 
 
48 
55 
 
19 
173 
Statistics for two-way 
contingency table analysis  
 
p-value† 
 
Cramer’s V†† 
 
 
 
 
<0.001 
 
0.42 
† p-value calculated from Chi-square test on contingency table. †† Cramer’s V statistic 
(value can range from 0 to 1) measures the strength of association between the two 
variables analyzed in the contingency table, with 1 indicating perfect association and 0 
indicating no association. 
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Table 4.5. Multivariate Cox proportional hazards analysis for the 225 ER+ samples in the 
Chang et al. 2005 dataset in relation to Relapse-Free Survival and Overall Survival. 
Multivariate Cox proportional hazards analysis of (A) standard clinical prognostic factors 
alone or with (B) the 70-gene predictor, (C) Wound-response predictor, (D) Ma et al.’s 2-
gene predictor, (E) Recurrence Score predictor, or (F) intrinsic subtypes in relation to 
Relapse-Free Survival and Overall Survival. Size was a binary variable (0= diameter of 
2cm or less, 1= greater than 2cm); age was a continuous variable formatted as decade-
years; hazard ratios for intrinsic subtypes were calculated relative to the Luminal A 
subtype. Variables found to be significant (p<0.05) in the Cox proportional hazards 
model are shown in bold. 
 
 
A.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
0.54 (0.35-0.82) 
 
2.11 (1.12-3.98) 
 
2.83 (1.49-5.38) 
 
1.41 (0.88-2.26) 
 
2.11 (1.06-4.21) 
 
2.92 (1.26-6.73) 
 
0.37 (0.18-0.73) 
 
0.005 
 
0.021 
 
0.002 
 
0.15 
 
0.034 
 
0.012 
 
0.004 
 
0.56 (0.31, 0.99) 
 
3.28 (1.08, 9.94) 
 
7.36 (2.51, 21.5) 
 
1.33 (0.71, 2.49) 
 
2.11 (0.81, 5.53) 
 
2.16 (0.69, 6.72) 
 
0.52 (0.20, 1.32) 
 
 
0.047 
 
0.035 
 
<0.001 
 
0.36 
 
0.13 
 
0.18 
 
0.17 
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B.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
70-gene predictor  
(poor vs. good) 
 
0.65 (0.42-0.99) 
 
1.24 (0.63-2.44) 
 
1.20 (0.59-2.48) 
 
1.45 (0.91-2.31) 
 
1.73 (0.88-3.40) 
 
2.70 (1.12-6.49) 
 
0.37 (0.18-0.74) 
 
 
3.88 (2.15-7.02) 
 
0.047 
 
0.53 
 
0.61 
 
0.12 
 
0.11 
 
0.027 
 
0.005 
 
 
<0.001 
 
0.68 (0.38, 1.22) 
 
1.75 (0.55, 5.55) 
 
2.72 (0.85, 8.66) 
 
1.41 (0.76, 2.61) 
 
1.81 (0.71, 4.60) 
 
2.32 (0.69, 7.80) 
 
0.47 (0.18, 1.22) 
 
 
5.47 (2.13, 14.1) 
 
 
0.20 
 
0.34 
 
0.091 
 
0.28 
 
0.21 
 
0.17 
 
0.12 
 
 
<0.001 
 
 
C.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy  
 
Wound-response  
(activated vs. quiescent) 
 
0.50 (0.32-0.78) 
 
1.60 (0.83-3.05) 
 
2.10 (1.09-4.05) 
 
1.39 (0.87-2.21) 
 
1.87 (0.94-3.73) 
 
2.19 (0.92-5.20) 
 
0.39 (0.20-0.78) 
 
 
2.95 (1.42-6.14) 
 
 
0.002 
 
0.16 
 
0.026 
 
0.17 
 
0.076 
 
0.075 
 
0.008 
 
 
0.004 
 
 
0.49 (0.27, 0.90) 
 
2.41 (0.78, 7.39) 
 
5.24 (1.76, 15.6) 
 
1.32 (0.71, 2.46) 
 
1.85 (0.71, 4.82) 
 
1.61 (0.50, 5.17) 
 
0.56 (0.22, 1.45) 
 
 
4.03 (1.20, 13.5) 
 
 
0.022 
 
0.12 
 
0.003 
 
0.38 
 
0.21 
 
0.42 
 
0.23 
 
 
0.024 
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D.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy  
 
Ma et al. 2-gene ratio  
(high vs. low) 
 
0.54 (0.35-0.84) 
 
2.08 (1.10-3.93) 
 
2.99 (1.55-5.74) 
 
1.42 (0.89-2.26) 
 
2.15 (1.08-4.29) 
 
2.99 (1.29-6.92) 
 
0.36 (0.18-0.72) 
 
 
0.81 (0.51-1.29) 
 
0.006 
 
0.023 
 
0.001 
 
0.14 
 
0.030 
 
0.010 
 
0.004 
 
 
0.38 
 
0.56 (0.31, 0.99) 
 
3.28 (1.08, 9.92) 
 
7.42 (2.51, 21.9) 
 
1.34 (0.72, 2.49) 
 
2.12 (0.80, 5.55) 
 
2.16 (0.69, 6.70) 
 
0.52 (0.20, 1.32) 
 
 
0.97 (0.52, 1.79) 
 
0.048 
 
0.036 
 
<0.001 
 
0.36 
 
0.13 
 
0.18 
 
0.17 
 
 
0.91 
 
 
E.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
Intermediate vs. Low 
recurrence score 
 
High vs. Low  
recurrence score 
 
0.49 (0.32-0.75) 
 
1.42 (0.72, 2.79) 
 
1.69 (0.83, 3.41) 
 
1.52 (0.96, 2.42) 
 
1.97 (1.00, 3.87) 
 
3.10 (1.32, 7.26) 
 
0.40 (0.20, 0.80) 
 
 
0.82 (0.27, 2.46) 
 
 
2.59 (1.44, 4.65) 
 
0.001 
 
0.32 
 
0.15 
 
0.073 
 
0.049 
 
0.009 
 
0.009 
 
 
0.72 
 
 
0.001 
 
 
0.50 (0.28, 0.90) 
 
1.83 (0.58, 5.77) 
 
3.26 (1.04, 10.2) 
 
1.54 (0.83, 2.86) 
 
1.75 (0.68, 4.47) 
 
2.06 (0.66, 6.39) 
 
0.62 (0.24, 1.58) 
 
 
1.42 (0.27, 7.50)  
 
 
4.95 (1.82, 13.4) 
 
 
0.021 
 
0.30 
 
0.042 
 
0.17 
 
0.24 
 
0.21 
 
0.32 
 
 
0.68 
 
 
0.002 
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F.       Relapse-Free survival   Overall survival 
Variable 
 
Hazard Ratio 
(95% CI) 
p-value Hazard Ratio 
(95% CI) 
p-value 
 
 
Age, per decade 
 
Tumor grade 2 vs. 1 
 
Tumor grade 3 vs. 1 
 
Size 
 
1-3 vs. 0 positive nodes 
 
>3 vs. 0 positive nodes 
 
Hormonal or chemotherapy 
vs. no adjuvant therapy 
 
Luminal B 
 
Normal-like, HER2+/ER-, 
or Basal-like 
 
0.52 (0.33, 0.81) 
 
1.40 (0.72, 2.71) 
 
1.62 (0.82, 3.18) 
 
1.66 (1.03, 2.65) 
 
1.82 (0.92, 3.59) 
 
2.34 (0.96, 5.68) 
 
0.34 (0.16, 0.68) 
 
 
4.40 (2.47, 7.84) 
 
2.51 (1.38, 4.58) 
 
 
0.004 
 
0.32 
 
0.16 
 
0.036 
 
0.085 
 
0.061 
 
0.003 
 
 
<0.001 
 
0.003 
 
 
0.57 (0.31, 1.04) 
 
2.48 (0.80, 7.70) 
 
4.92 (1.62, 14.9) 
 
1.51 (0.80, 2.82) 
 
1.89 (0.73, 4.89) 
 
1.98 (0.60, 6.54) 
 
0.49 (0.18, 1.29) 
 
 
2.81 (1.33, 5.91) 
 
1.92 (0.84, 4.37) 
 
 
0.065 
 
0.12 
 
0.005 
 
0.20 
 
0.19 
 
0.26 
 
0.15 
 
 
0.006 
 
0.12 
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Table 4.6. Comparison of predictors for 225 ER+ patients. 
 
Intrinsic 
Subtype # Recurrence Score 70-gene Wound-Response 2-gene 
Low 1 good 0 Quiescent 0 Low 1 
Intermediate 1             
Basal-like 7 high 5 poor 7 Activated 7 high 6 
Low 68 good 87 Quiescent 45 Low 77 
Intermediate 13             
Luminal A 121 high 40 poor 34 Activated 76 high 44 
Low 2 good 9 Quiescent 4 Low 30 
Intermediate 2             
Luminal B 55 high 51 poor 46 Activated 51 high 25 
Low 1 good 2 Quiescent 0 Low 5 
Intermediate 0             
HER2+/ER- 18 high 17 poor 16 Activated 18 high 13 
Low 15 good 15 Quiescent 11 Low 9 
Intermediate 2             
Normal-like 24 high 7 poor 9 Activated 13 high 15 
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Table 4.7. Two-way contingency table analysis measuring the association between the 
70-gene, Wound-response, and Recurrence Score predictors in the ER+ 225-sample 
dataset. 
 
A.  
 
  Wound-Response  
 
  Quiescent        Activated 
             (# of patients) 
Two-way contingency table 
 
 
 
 
70-gene predictor  
               Good 
                Poor 
 
47 
13 
 
66 
99 
Statistics for two-way 
contingency table analysis  
 
p-value† 
 
Cramer’s V†† 
 
 
 
 
<0.001 
 
0.34 
 
B.  
 
  Recurrence Score  
 
  Low or Int.        High 
          (# of patients) 
Two-way contingency table 
 
 
 
 
70-gene predictor  
               Good 
                Poor 
 
83 
22 
 
30 
90 
Statistics for two-way 
contingency table analysis  
 
p-value† 
 
Cramer’s V†† 
 
 
 
 
<0.001 
 
0.54 
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C. 
 
  Recurrence Score  
 
  Low or Int.        High 
          (# of patients) 
Two-way contingency table 
 
 
 
 
Wound Response  
                Quiescent 
                Activated 
 
47 
58 
 
13 
107 
Statistics for two-way 
contingency table analysis  
 
p-value† 
 
Cramer’s V†† 
 
 
 
 
<0.001 
 
0.38 
† p-value calculated from Chi-square test on contingency table. †† Cramer’s V statistic 
(value can range from 0 to 1) measures the strength of association between the two 
variables analyzed in the contingency table, with 1 indicating perfect association and 0 
indicating no association. 
 
  107 
  
 
FIGURES 
 
 
Figure 4.1. Survival analysis of the 295 patients stratified according to 5 different gene 
expression based predictors. Kaplan-Meier survival plots for Relapse Free Survival (left 
panels) and Overall Survival (right panels) are shown for the 295 patients stratified 
according to Intrinsic Subtypes (A, B), Recurrence Score (C, D), 70-gene profile (E, F), 
Wound-Response (G, H) and 2-gene ratio predictor (I, J). All reported p-values are based 
upon a log-rank test. 
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Figure 4.2. Survival analysis of the 225 ER+ patients stratified according to 5 different 
gene expression based predictors. Kaplan-Meier survival plots for Relapse Free Survival 
(left panels) and Overall Survival (right panels) are shown for the 225 ER+ patients 
stratified according to Intrinsic Subtypes (A, B), Recurrence Score (C, D), 70-gene 
profile (E, F), Wound-Response (G, H) and 2-gene ratio predictor (I, J). All reported p-
values are based upon a log-rank test. 
 
  
 
CHAPTER 5:  Expression profiles can predict response to neoadjuvant 
chemotherapy in breast cancer patients 
 
ABSTRACT 
Background 
The identification of markers predictive of neoadjuvant chemotherapy response would be 
an important advance. Therefore, we sought to identify gene expression profiles 
predictive of neoadjuvant response. 
 
Methods 
DNA microarray analysis was performed on pre-treatment core biopsies from locally 
advanced breast cancer patients receiving four cycles of neoadjuvant doxorubicin plus 
cyclophosphamide (AC) followed by four cycles of paclitaxel (T) or paclitaxel and 
trastuzumab (TH). In total, 44 patients receiving chemotherapy yielded successful pre-
treatment core biopsy and microarray.  
 
Results 
Ten-fold cross-validated supervised analyses using the pre-treatment microarray data 
identified gene expression patterns that accurately predicted (1) clinical response after 
four cycles of treatment, (2) clinical response after successful completion of all eight 
  110 
  
cycles of treatment, and (3) overall clinical response for these 44 patients. In contrast, no 
significant association was detected between any of the response outcomes measured and 
the standard clinical parameters of ER status, node status, or grade.  
 
Conclusions 
These results suggest that gene expression profiling may lead to clinically useful 
predictors of neoadjuvant chemotherapy response. The gene expression patterns reported 
here may provide the means of selecting patients for AC-T(H) neoadjuvant therapy.  
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INTRODUCTION 
Neoadjuvant chemotherapy (treatment before primary surgery) has been widely 
used as a component of the standard of care for locally advanced breast cancer patients. 
Although neoadjuvant and adjuvant chemotherapy have similar efficacy in terms of 
disease-free and overall survival rates, neoadjuvant chemotherapy has been shown to 
improve breast-conserving operability in locally advanced breast cancers1. Another 
advantage of neoadjuvant chemotherapy is that it allows for the direct and timely 
observation of tumor treatment response. Response (pathologic complete response [pCR] 
or clinical complete response) to neoadjuvant chemotherapy has been correlated with 
improved long-term disease-free and overall survival1-7. Currently, there is no clinically 
useful predictor of neoadjuvant chemotherapy response. Such a predictor would be of 
significant value; by identifying patients unlikely to benefit from therapy, it would spare 
them from treatment-associated toxicities and allow them to be more efficiently selected 
to receive alternative approaches.  
Recently, studies have focused on using gene expression profiling to identify 
expression patterns predictive of chemotherapy response8-13. Using gene expression 
profiling shows promise in identifying patterns predictive of chemotherapy response as it 
has already allowed the classification of breast tumors into five molecular subtypes 
(Luminal A, Luminal B, Basal-like, HER2+/ER- and Normal Breast-like) that show 
significant differences in patient outcome14,15. Therefore, we determined if pre-treatment 
gene expression patterns could predict response to the following neoadjuvant 
chemotherapy regimen: doxorubicin plus cyclophosphamide followed by paclitaxel with 
or without trastuzumab. 
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MATERIALS AND METHODS 
Patients and study design.  A phase II study run at UNC-CH (Trial L9819; Trial PI: 
Lisa Carey) of the neoadjuvant administration of four cycles of doxorubicin plus 
cyclophosphamide (AC), followed by four cycles of paclitaxel (T) or paclitaxel plus 
trastuzumab (TH) was performed on a set of locally advanced operable breast cancer 
patients (for complete details see Carey et al.16). Patients received AC-TH if their tumors 
showed HER2-positivity as defined by Carey et al.16 The main purpose of this phase II 
study was to determine the cardiotoxicity of neoadjuvant doxorubicin plus 
cyclophosphamide followed by paclitaxel plus trastuzumab. As part of this study, 
pretreatment core biopsies were obtained from patients; RNA from these biopsies was 
used for our prediction of response analysis described here. Clinical response to 
neoadjuvant therapy was evaluated after the first four cycles of treatment and after all 
eight cycles of treatment, following Response Evaluation Criteria in Solid Tumors 
(RECIST), with complete response (CR) defined as no clinical evidence of tumor, partial 
response (PR) as ≥30% decrease in the longest diameter, progression (PD) as ≥20% 
increase in the longest diameter, and stable disease (SD) as all other tumor responses17. 
Pathologic response in the post-neoadjuvant chemotherapy surgical specimen was 
defined by residual disease in the breast or axillary lymph nodes according to the revised 
2003 AJCC TNM staging system.  
 
RNA isolation and microarray hybridization. Total RNA samples from the 
pretreatment biopsies were prepared using Qiagen RNAeasy kits. An Agilent Bioanalyzer 
was used to determine sample quality. Only those samples giving ≥1μg Total RNA and 
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discernable 18S and 28S peaks were used for microarray analysis. Total RNA 
amplification and labeling were done as previously described18. Microarray 
hybridizations were performed on Agilent Human microarrays using 2μg of Cy3-labeled 
common reference sample19 and 2μg of Cy5-labeled experimental sample. Microarrays 
were hybridized overnight, washed, dried, and scanned as described18. Microarray image 
files were analyzed with GenePix Pro 4.1 and loaded into the UNC-CH Microarray 
Database (https://genome.unc.edu/).  
 
Microarray analysis and prediction of response.  Data from microarray experiments 
were calculated as described18. Genes were excluded from data analysis if they did not 
have signal intensity ≥30 in both channels for ≥70% of the experiments. To predict 
response, the gene expression data for the 44 pre-treatment samples was used and the 
“supervising parameters” were clinical response after cycles 4 and 8, overall clinical 
response, and pathologic complete response (pCR). The difference between overall 
clinical response and clinical response after cycle 8 is that for a patient to be evaluated for 
the latter, she would had to have completed all 8 therapy cycles. In contrast, overall 
clinical response is evaluated after the last successfully completed therapy cycle (not 
necessarily cycle 8).  
Four statistical classification methods were used to predict chemotherapy 
response using the pre-treatment gene expression data: a k-Nearest Neighbor Classifier 
(k-NN with k=1, 3, 5, or 7) with either Euclidean distance or one-minus-Spearman-
correlation as the distance function and a Class Nearest Centroid (CNC) classifier with 
either Euclidean distance or one-minus-Spearman-correlation as the distance function20. 
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To evaluate prediction accuracy, each of the four prediction methods underwent 10-fold 
cross validation (CV); in a given round of CV, each predictor using n genes (how the n 
genes were selected is described below) was trained on 90% of the samples and used to 
make predictions on the remaining 10%, with this procedure repeated 9 more times such 
that every sample was “left out” exactly once. The prediction accuracies for each of the 
10 iterations were averaged together and this average prediction accuracy was recorded 
for each prediction method with n genes. n was increased for subsequent rounds of CV. 
For each response variable, the set of n genes that gave the highest average prediction 
accuracy during CV was determined and reported for each prediction method (Table 3).  
Each prediction method required a gene/feature selection step to identify genes 
associated with each “class” (i.e. CR vs. PR+SD). For all 4 prediction methods, we used 
a gene selection method first described by Dudoit et al.21; the genes were identified in the 
training set according to the ratio of between-class to within-class sums of squares. The 
top n-ranked genes were used during each round of CV. The number of cases in our study 
was relatively small (44), therefore, we did not break our data into training and test sets 
but instead, performed 10-fold CV using the four statistical prediction methods to avoid 
over-fitting caused by using a single prediction method or fortuitous training and test set 
randomizations.  
 
RESULTS 
Patient characteristics and response rates. 44 patients enrolled in the L9819 study 
gave a successful pre-treatment core biopsy and microarray. Patient characteristics are 
summarized in Table 1. Of these 44 patients, 24 and 11 successfully completed AC-T and 
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AC-TH therapy, respectively. The patient subgroups receiving AC-T or AC-TH did not 
significantly differ from each other in age, grade, stage, ER or PR status. Clinical 
response data for the 44 patients is summarized in Table 2. Patient subgroups receiving 
AC-T or AC-TH did not significantly differ from each other in response rates (overall 
clinical response, clinical response after 4 and 8 treatment cycles, and pCR).  
 
Analysis of tumor samples using the breast intrinsic gene set. Chemotherapy response 
is likely a multi-factorial process, therefore, we examined whether gene expression 
patterns were able to capture response-associated biological features. To investigate the 
gene expression data, we first hierarchically clustered22 the 44 pre-treatment samples 
using the 1300-gene “breast intrinsic” gene set (developed by Hu et al.23) that identifies 
the intrinsic breast tumor subtypes (Luminal, HER2+/ER-neg, Basal-like). The results 
show that the main intrinsic subtypes (Figure 1) were identifiable in this patient dataset. 
As seen in previous studies23, the proliferation gene cluster was found to have the highest 
expression in Basal-like tumors. 
 
Association of response with clinical parameters and breast intrinsic subtype. We 
explored how conventional clinical parameters performed in predicting response. Using 
either (1) all 44 patients, (2) just those receiving AC-T, or (3) just those receiving AC-
TH, neither ER status, PR status, node status, grade, or tumor size were significantly 
correlated with pCR or any other response variable according to Chi-squared analysis. 
Other studies have also found that the standard clinical parameters show weak to no 
association with neoadjuvant chemotherapy response24.  
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We next examined response rates within the intrinsic molecular subtypes. Rouzier 
et al.25 reported a strong association (p=0.002) between pCR rate and the Basal-like and 
HER2+/ER- subtypes. In the L9819 study, using either (1) all 44 patients, (2) just those 
receiving AC-T, or (3) just those receiving AC-TH, we did not see a statistically 
significant association between subtype and pCR or any other response variable (overall 
clinical response, clinical response after 4 and 8 treatment cycles). Among all 44 patients, 
2/11 (18.2%) basal-like, 2/15 (13.3%) HER2+/ER-, and 2/16 (12.5%) luminal tumors 
showed pCR. Among all 44 patients, the association between subtype and clinical 
response after 4 treatment cycles was not significant (p=0.17), but a trend was evident: 
10/12 (83.3%) basal-like, 8/16 (50%) HER2+/ER-, and 9/16 (56.3%) luminal tumors 
showed response (complete or partial) after 4 treatment cycles, which mimics the finding 
of Rouzier et al.25 in that the highest response rates were seen in the Basal-like subtype. 
 
Prediction of neoadjuvant chemotherapy response. We performed “supervised 
analyses” on the pretreatment gene expression data and determined the 10-fold Cross 
Validation (CV) error rates for predicting (1) pCR, (2) overall response, (3) response 
after 4 treatment cycles, and (4) response after 8 treatment cycles. Table 3 shows that 10-
fold CV analyses using the Class Nearest Centroid and k-Nearest Neighbor classification 
methods yielded gene expression profiles/predictors that accurately classified tumors 
according to (1) overall response: clinical complete response (CR) vs. non-CR (75-77% 
accuracy), (2) clinical response (partial or complete) vs. non-response after cycle 4 (73-
77% accuracy), and (3) CR vs. non-CR after cycle 8 (79-83% accuracy). We could not 
accurately classify tumors according to pCR (<60% accuracy), which we speculate is due 
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to the fact that the low number of samples showing pCR (n=6) was not enough to 
generate a reliable predictor. Each of the four prediction methods achieved similar 
accuracies when used to predict a given response variable (Table 3). Prediction of ER 
status is included as a positive control for our gene expression-based predictors; it 
represents the upper threshold of how good a predictor can be (86-89% accuracy) on this 
dataset, providing a benchmark against which the chemotherapy response predictors can 
be judged.  
Using the gene lists identified in 10-fold CV as being predictive of response 
(Table 3, highlighted in blue), we hierarchically clustered22 the pretreatment biopsy 
samples to better understand the predictive genes and their relationships to each other. 
Figure 2 shows the hierarchical clustering of tumors using the 54-gene set predictive of 
response after treatment cycle 4 (75% accuracy, 78% sensitivity, 71% specificity in 10-
fold CV analysis using the Euclidean nearest centroid method) (Note: the classification of 
samples into clusters and the associated accuracies observed in Figures 2-4 are different 
from those observed in the 10-fold CV analysis shown in Table 3. The clusters are for 
illustrative purposes/better understanding of the predictive gene sets only). Using the 
program EASE26, the Gene Ontology (GO) categories “DNA binding” and 
“nucleotide/nucleic acid metabolism” were over-represented relative to chance in the 
gene set highly expressed in tumors showing response at cycle 4 (Figure 2, top gene 
dendrogram branch).  
Figure 3 shows the hierarchical clustering of tumors using the 70-gene set 
predictive of overall response (75% accuracy, 72% sensitivity, 77% specificity in 10-fold 
CV analysis using the Euclidean nearest centroid method). Interestingly, the complete 
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responders in Figure 3 showed high expression of caspase-9, which promotes apoptosis27-
29. According to EASE, the GO category “ATP-dependent helicase activity” was over-
represented relative to chance in the gene set highly expressed in tumors showing overall 
complete response.  
Figure 4 shows the hierarchical clustering of tumors using the 72-gene set 
predictive of response after 8 treatment cycles (79% accuracy, 80% sensitivity, 79% 
specificity in 10-fold CV analysis using the Euclidean nearest centroid method). EASE 
showed that the GO categories “apoptosis/programmed cell death” and “positive 
regulation of apoptosis” were over-represented relative to chance in the gene set highly 
expressed in tumors showing complete response at cycle 8. Some of the pro-apoptotic 
genes highly expressed in complete responders relative to non-complete responders 
included caspases 4 and 5 and PACAP. These results suggest that in the pre-treatment 
samples, the high expression of proapoptotic genes are associated with and may partly 
explain chemotherapy response. 
 
DISCUSSION 
In this work, we examined whether pre-treatment gene expression patterns could 
predict response to AC-T(H) neoadjuvant therapy. 10-fold CV analysis identified gene 
expression patterns with prediction accuracy rates of 75-77% for overall response, 73-
77% for response after cycle 4, and 79-83% for response after cycle 8 (Table 3). The 
accuracy rates achieved are encouraging and warrant further validation.  
 We speculate that the 72-gene set predictive of response after 8 treatment cycles 
may represent a general mechanism of chemotherapy response. This gene set was 
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significantly enriched for pro-apoptotic genes. Findings from other studies indicate that 
apoptosis genes may be important in a general chemotherapy response; several reports 
studying breast tumor response to different chemotherapy regimens all indicate that in 
pretreatment samples, the high expression of apoptosis-related genes is associated with 
response9,10,30-32. Currently, we are testing the hypothesis that our 72-gene set may 
represent a general predictor of chemotherapy response using additional data sets of 
neoadjuvantly treated patients. 
 To date, three other published studies have attempted to predict neoadjuvant 
chemotherapy response using gene expression8,10,11. The prediction accuracies achieved 
by our gene expression-based predictors are similar to those achieved by the predictors 
developed by Chang et al.10 and Ayers et al.8: their predictors showed accuracies of 88% 
for predicting docetaxel clinical response and 78% for predicting pCR to paclitaxel + 
fluorouracil + doxorubicin + cyclophosphamide, respectively. In contrast, Hannemann et 
al.11 could not find a gene expression pattern from pretreatment FNAC samples that was 
capable of predicting pCR for patients receiving doxorubicin and cyclophosphamide or 
doxorubicin and docetaxel. Clearly, additional studies are needed with larger sample 
sizes, however, some common themes in the predictive gene expression patterns are 
evident, including apoptosis as an important feature. It is encouraging that genes 
identified in the predictors make biological sense and suggest our predictors are 
appropriately tracking response. 
Our results indicate that gene expression profiling may lead to clinically useful 
predictors of neoadjuvant chemotherapy response. Information regarding the intrinsic 
subtypes may also contribute to prediction assay development. We believe that the gene 
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expression-based predictors identified here have the potential to be clinically useful and 
warrant further validation using additional datasets as they emerge. 
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TABLES 
Table 5.1. Patient characteristics of the L9819 dataset.  
 
  
L9819 dataset (n=44) 
 
No. of pts (%) 
 
Age 
        Median (range) 
 
47 (30 to 79) 
Stage 
         I 
        IIA 
        IIB 
        IIIA 
        IIIB 
        IIIC 
        IV 
 
0 (0%) 
5 (11.4%) 
10 (22.7%) 
18 (40.9%) 
7 (15.9%) 
1 (2.3%) 
3 (6.8%) 
ER status 
        + 
        - 
        n.a. 
 
21 (48%) 
23 (52%) 
- 
 
Grade 
       1 
       2 
       3 
       n.a. 
 
5 (11.4%) 
7 (15.9%) 
25 (56.8%) 
7 (15.9%) 
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Table 5.2.  Neoadjuvant Chemotherapy Response data for the L9819 dataset.  
 
  
Response after 4 
cycles 
 
Response after 8 
cycles 
 
 
 
Overall response 
 
pCR 
 
Response data 
for all 44 pts. 
 
 
8 CR    (18.2%) 
19 PR   (43.2%) 
15 SD   (34.1%) 
2 PD     (4.5%) 
 
10 CR   (34.5%) 
12 PR    (41.4%) 
6 SD      (20.7%) 
1 PD      (3.4%) 
 
 
18 CR    (40.9%) 
16 PR    (36.4%) 
9 SD      (20.5%) 
1 PD      (8.3%) 
 
6 pCR                      (13.6%) 
36 non-pCR             (81.8%) 
2 n.a.                        (4.5%) 
 
Abbreviations: pCR=pathologic complete response; CR=clinical complete response; 
PR=partial response; SD=stable disease; PD=progressive disease. 
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Table 5.3. Accuracy (as determined by 10-fold cross validation) of various classification 
methods for the 44 tumor samples that yielded pre-treatment microarray data from the 
L9819 study. Classification methods were used to predict (A) response at cycle 4, (B) 
response after completion of all 8 treatment cycles, (C) overall response, and (D) ER 
status. 
 
A. Prediction of Response at Cycle 4 (27 responders [8 CRs and 19 PRs] vs. 17 non-
responders [15 SDs and 2 PDs]) 
Classification 
method 
gene 
# acc. 
True 
+ 
True 
- 
False 
+ 
False 
- sens. spec. PPV NPV 
Spearman 
Nearest 
Centroid 53 0.727 20 12 5 7 0.741 0.706 0.800 0.632 
Euclidean 
Nearest 
Centroid 54 0.75 21 12 5 6 0.778 0.706 0.808 0.667 
Spearman  
k-NN (k=7) 37 0.727 21 11 6 6 0.778 0.647 0.778 0.647 
Euclidean 
k-NN (k=7) 53 0.773 21 13 4 6 0.778 0.765 0.840 0.684 
 
Average  0.744     0.769 0.706 0.806 0.657 
 
 
B. Prediction of Response at Cycle 8 (10 CRs vs. 19 non-CRs [12 PRs, 6 SDs, and 1 PD]) 
Classification 
method 
gene 
# acc. 
True 
+ 
True 
- 
False 
+ 
False 
- sens. spec. PPV NPV 
Spearman 
Nearest 
Centroid 55 0.793 8 15 4 2 0.800 0.789 0.667 0.882 
Euclidean 
Nearest 
Centroid 72 0.793 8 15 4 2 0.800 0.789 0.667 0.882 
Spearman  
k-NN (k=5) 76 0.793 8 15 4 2 0.800 0.789 0.667 0.882 
Euclidean 
k-NN (k=5) 63 0.828 8 16 3 2 0.800 0.842 0.727 0.889 
 
Average  0.802     0.800 0.803 0.682 0.884 
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C. Prediction of Overall Response (18 CRs vs. 26 non-CRs [16 PRs, 9 SDs, and 1 PD]) 
Classification 
method 
gene 
# acc. 
True 
+ 
True 
- 
False 
+ 
False 
- sens. spec. PPV NPV 
Spearman 
Nearest 
Centroid 54 0.75 14 19 7 4 0.778 0.731 0.667 0.826 
Euclidean 
Nearest 
Centroid 70 0.75 13 20 6 5 0.722 0.769 0.684 0.800 
Spearman  
k-NN (k=5) 55 0.773 14 20 6 4 0.778 0.769 0.700 0.833 
Euclidean 
k-NN (k=5) 37 0.75 12 21 5 6 0.667 0.808 0.706 0.778 
 
Average  0.756     0.736 0.769 0.689 0.809 
 
 
D. Prediction of ER status (21 ER+ vs. 23 ER-) 
Classification 
method 
gene 
# acc. 
True 
+ 
True 
- 
False 
+ 
False 
- sens. spec. PPV NPV 
Spearman 
Nearest 
Centroid 50 0.864 19 19 4 2 0.905 0.826 0.826 0.905 
Euclidean 
Nearest 
Centroid 50 0.864 19 19 4 2 0.905 0.826 0.826 0.905 
Spearman  
k-NN (k=3) 50 0.886 19 20 3 2 0.905 0.870 0.864 0.909 
Euclidean 
k-NN (k=3) 50 0.864 19 19 4 2 0.905 0.826 0.826 0.905 
 
Average  0.870     0.905 0.837 0.835 0.906 
 
Note: Accuracies, etc. highlighted in blue are for the gene lists used to cluster tumors in 
Figures 2-4. Average accuracies, etc. across the prediction methods are highlighted in 
red. “True +” refers to number of responders correctly identified. “True –” refers to 
number of non-responders correctly identified. “False +” refers to number of non-
responders incorrectly identified. “False –” refers to number of responders incorrectly 
identified. 
 
Abbreviations: acc.=accuracy; sens.=sensitivity; spec.=specificity; PPV=positive 
predictive value; NPV=negative predictive value; k-NN=k-nearest neighbors; 
CR=clinical complete response; PR=partial response; SD=stable disease; PD=progressive 
disease. 
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FIGURES 
 
 
Figure 5.1. Hierarchical cluster analysis of L9819 pre-treatment tumor samples using the 
1300-gene “intrinsic breast” gene set developed by Hu et al. groups tumors into the 
intrinsic subtypes. A. Scaled-down representation of the complete cluster diagram. B. 
Basal epithelial, C. Proliferation, D. HER2+, and E. Luminal gene clusters.  
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Figure 5.2. Hierarchical cluster analysis of L9819 pre-treatment tumor samples using the 
54-gene set predictive of clinical response after 4 treatment cycles. Blue and yellow 
dendrogram branches indicate responders (complete or partial) and non-responders 
(stable or progressive disease), respectively. 
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Figure 5.3. Hierarchical cluster analysis of L9819 pre-treatment tumor samples using the 
70-gene set predictive of overall response. Blue and yellow dendrogram branches 
indicate complete and non-complete overall responders, respectively.   
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Figure 5.4. Hierarchical cluster analysis of L9819 pre-treatment tumor samples using the 
72-gene set predictive of clinical response after completion of all 8 treatment cycles. Blue 
and yellow dendrogram branches indicate complete and non-complete responders, 
respectively. 
 
  
 
CHAPTER 6:  DISCUSSION 
 Currently, many breast cancer patients are being given lengthy and expensive 
treatments associated with significant toxicity and morbidity. Some of these patients will 
receive no benefit in survival while others would have achieved good outcomes without 
additional treatments. This work has aimed to remedy this situation using gene 
expression profiling. First, we developed an expression-based predictor of outcome for 
Estrogen Receptor (ER) and/or Progesterone Receptor (PR)-positive breast cancer 
patients using biological differences among these tumors. Second, we used a recently 
developed multivariate analysis tool (DWD) to validate and objectively define the 
“intrinsic” subtypes as a predictor/prognosticator of breast cancer patient outcomes by 
using independent datasets generated on differing microarray platforms. Third, using a 
single patient dataset, we determined that there was significant concordance in outcome 
predictions made by several different gene expression profiles (developed on different 
platforms by different laboratories), which showed little overlap in gene identity. Lastly, 
we developed gene expression-based predictors for response to neoadjuvant 
chemotherapy using pre-treatment microarray data. 
From the results of this work, we propose the following decision tree for how to 
treat breast cancer patients (Figure 1), which will of course, need much more validation 
and testing before routine clinical use. First, using the intrinsic subtype single sample 
predictor (SSP) introduced in Chapter 3, the patient would be objectively classified as 
  133 
  
having either luminal, HER2+/ER-, or basal-like breast cancer. If the patient’s tumor 
were determined to be of the luminal subtype, we would then apply the Group IE-IIE 
predictor introduced in Chapter 2. If the tumor is classified as Group IE, we hypothesize 
that all that is needed for treatment would be hormone therapy (i.e. tamoxifen), and that 
this patient might be spared the chemotherapy regimen that they would normally be 
prescribed. If the tumor is classified as Group IIE, we would then first examine the 
tumor’s HER2 status to determine whether trastuzumab (monoclonal antibody that binds 
to HER2) should be part of the treatment regimen (i.e. HER2+ tumors will receive 
trastuzumab). Regardless of HER2 status, if the tumor is classified as Group IIE, we 
would also apply the L9819 72-gene chemotherapy response predictor (introduced in 
Chapter 5), which we believe can be used to predict general chemotherapy response. If 
the tumor is predicted to respond to chemotherapy by the L9819 predictor, we would 
include (neo)adjuvant chemotherapy and tamoxifen in the treatment regimen for these 
patients (however, the data suggests that Group IIE tumors are resistant to tamoxifen, 
which must be formally tested in randomized trials). If the tumor is predicted to not 
respond to chemotherapy by the L9819 predictor, the patient would be given an 
alternative therapy and perhaps be considered for entry into trials containing new 
biological agents. The hope is that these patients unlikely to benefit from conventional 
chemotherapy regimens will in addition to avoiding unnecessary chemotherapy-
associated morbidity, have the opportunity to benefit from exposure to potentially 
effective novel agents.  
If the patient’s tumor were determined to be of the HER2+/ER- subtype, the 
patient will receive trastuzumab (currently some HER2+/ER- tumors are believed to be 
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resistant to trastuzumab, but no predictor to determine resistance yet exists). In addition, 
we would use the L9819 general chemotherapy response predictor to determine if 
conventional (neo)adjuvant chemotherapy should be added to the treatment regimen in 
the case of those predicted to respond, and for those predicted to not respond, alternative 
regimens with novel agents might be considered. Finally, if the patient’s tumor were 
determined to be of the Basal-like subtype, at present we believe the best course of action 
would be to use the L9819 general chemotherapy response predictor to determine if 
(neo)adjuvant chemotherapy should be given to the patient, and again, those predicted not 
to respond might be offered therapies containing novel biological agents like HER1 
inhibitors. We hope that with improved understanding of the basal-like subtype, novel 
therapies tailored to this particular subtype of breast cancer will be developed to 
complement or perhaps supplant chemotherapy as the treatment of choice. For example, 
recent studies suggest that this subtype may benefit from therapy targeting the epidermal 
growth factor receptor (HER1) and/or the pathway it regulates1,2. Clinical trials are 
currently underway to determine the efficacy of HER1 inhibitors (i.e. cetuximab, 
gefitinib, and erlotinib) in basal-like tumors3.  
As stated earlier, the decision tree in Figure 1 will require rigorous validation and 
testing before routine clinical use. These validation studies should be done using cohorts 
with large enough sample size so that (1) the full diversity of the target population will be 
represented and (2) the study will have the necessary statistical power to determine if the 
predictor in question does indeed improve current treatment decision-making strategies. 
When possible, randomized controlled trials should be used in the validation process4. 
For example, to test our hypothesis discussed earlier that Group IE tumors may benefit 
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from tamoxifen but not benefit significantly from chemotherapy, we could use a clinical 
trial in which patients classified as Group IE are randomly assigned to receive either 
tamoxifen or tamoxifen and chemotherapy. The survival outcomes of those receiving 
tamoxifen alone or tamoxifen with chemotherapy would be compared. To test our 
hypothesis that Group IIE tumors do not benefit from tamoxifen but may benefit 
significantly from chemotherapy, we could use a clinical trial in which patients classified 
as Group IIE are randomly assigned to receive either tamoxifen alone, chemotherapy 
alone, or both tamoxifen and chemotherapy. The survival outcomes of these three 
treatment groups would then be compared, and our expected result would be that Group 
IIE patients receiving tamoxifen plus chemotherapy would have the same outcomes as 
those receiving chemotherapy alone. Other clinical trial designs as described by Sargent 
et al.4 could also be used to test these same hypotheses. When randomized clinical trials 
are not possible, retrospective case-control studies may be considered. 
We acknowledge that before gene expression-based predictors or prognosticators 
can be introduced to the clinic, the current expenses and required training involved need 
to be made less prohibitory for routine clinical use. The requirement for fresh frozen 
material for microarray analysis is also prohibitory. However, we are confident that these 
difficulties can be overcome in time with technological advances. For example, recent 
progress has been made to use formalin fixation and paraffin-embedded (FFPE) tissue 
samples to amplify RNA for microarray analysis5. In addition, RT-PCR (real-time 
reverse transcriptase polymerase chain reaction) assays can be used as an alternative to 
microarrays for the simultaneous analysis of hundreds of genes and can be employed to 
validate “expression signatures” initially identified in microarray analysis. Importantly, 
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RT-PCR assays can examine gene expression using limited amounts of RNA extracted 
from FFPE sections. 
In summary, this work has advanced the current knowledge of the heterogeneity 
of breast cancer and provides a means for improved prediction and prognostication for 
breast cancer patients. This work has shown that gene expression profiling can and will 
be clinically useful and will improve the treatment decision-making process for breast 
cancer patients. Provided that properly designed and rigorous validation studies are 
performed, we are confident gene expression profiling will be accepted for routine 
clinical use.  
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FIGURES 
 
 
 
Figure 6.1. Proposed decision tree to determine therapy for the newly diagnosed breast 
cancer patient. This decision tree makes use of three different gene expression-based 
predictors discussed in this work: (1) the Intrinsic Subtype Predictor (SSP) introduced in 
Chapter 3, (2) the Group IE-IIE predictor introduced in Chapter 2, and (3) the general 
chemotherapy response predictor (from the L9819 clinical study) introduced in Chapter 
5.  
 
 
 
